:: CLDF ::

Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals: Results from the PROP UP Study

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14781. Online ahead of print.

Marina Serper¹, Donna M Evon², Jipcy Amador³, Paul W Stewart³, Souvik Sarkar⁴, Anna S Lok⁵, Richard K Sterling⁶, Bryce B Reeve⁷, Carol E Golin⁸, K Rajender Reddy¹, Joseph K Lim⁹, Nancy Reau¹⁰, David R Nelson¹¹, Adrian M Di Bisceglie¹², Michael W Fried²

Progress towards hepatitis C virus elimination in high-income countries: an updated analysis

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14779. Online ahead of print.

Ivane Gamkrelidze¹, Jean-Michel Pawlotsky², Jeffrey V Lazarus³, Jordan J Feld⁴, Stefan Zeuzem⁵, Yanjun Bao⁶, Ana Gabriela Pires Dos Santos⁶, Yuri Sanchez Gonzalez⁶, Homie Razavi¹

Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C

Am J Gastroenterol. 2020 Dec 24;Publish Ahead of Print. doi: 10.14309/ajg.0000000000001095.Online ahead of print.

Jia Li¹, Stuart C Gordon, Yueren Zhou, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Loralee B Rupp, Sheri Trudeau, Mei Lu, CHeCS Investigators

Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond

Chem Rev. 2021 Jan 7. doi: 10.1021/acs.chemrev.0c00648. Online ahead of print.

Ashley N Matthew¹, Florian Leidner¹, Gordon J Lockbaum¹, Mina Henes¹, Jacqueto Zephyr¹, Shurong Hou¹, Desaboini Nageswara Rao¹, Jennifer Timm¹, Linah N Rusere¹, Debra A Ragland¹, Janet L Paulsen¹, Kristina Prachanronarong¹, Djade I Soumana¹, Ellen A Nalivaika¹, Nese Kurt Yilmaz¹, Akbar Ali¹, Celia A Schiffer¹

HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status

Clin Infect Dis. 2020 Dec 21;ciaa1869.doi: 10.1093/cid/ciaa1869. Online ahead of print.

Risha Irvin¹, Theresa Gamble², Jowanna Malone¹, Zhe Wang³, Ethan Wilson³, James P Hughes⁴, Jason Farley¹, Kenneth H Mayer⁵, Carlos Del Rio⁶, D Scott Batey⁷, Vanessa Cummings¹, Robert H Remien⁸, Chris Beyrer¹, Chloe L Thio¹

Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic

J Infect Dis. 2020 Nov 27;222(Supplement_9):S758-S772. doi: 10.1093/infdis/jiaa366.

Sahar Bajis¹, Tanya L Applegate¹, Jason Grebely¹, Gail V Matthews¹, Gregory J Dore¹

We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States

J Infect Dis. 2020 Nov 27;222(Supplement_9):S773-S781. doi: 10.1093/infdis/jiaa574.

Stacey B Trooskin^1 2, Gregory Dore³, Jay Kostman¹

Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56. doi: 10.1016/S2468-1253(20)30303-4.Epub 2020 Nov 18.

Fengyi Jin¹, Gregory J Dore², Gail Matthews², Niklas Luhmann³, Virginia Macdonald³, Sahar Bajis², Rachel Baggaley³, Bradley Mathers³, Annette Verster³, Andrew E Grulich²

Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?

J Infect Dis. 2020 Nov 27;222(Supplement_9):S794-S801. doi: 10.1093/infdis/jiaa420.

Matthew R Kappus^1 2, Cameron R Wolfe^1 2, Andrew J Muir^1 2

10.

Nontargeted Hepatitis C Screening in an Urban Emergency Department in New York City

J Emerg Med. 2020 Nov 16;S0736-4679(20)30970-7. doi: 10.1016/j.jemermed.2020.09.034.Online ahead of print.

Ethan A Cowan¹, Amreen Dinani², Samantha Brandspiegel¹, Clare O'Brien-Lambert¹, Joseph Zaheer¹, Erick Eiting¹, George Loo¹, Yvette Calderon¹

11.

Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals

Open Forum Infect Dis. 2020 Oct 23;7(11):ofaa514. doi: 10.1093/ofid/ofaa514.eCollection 2020 Nov.

Tatyana Kushner^1 2, Claire Park², Dana Masand², Brian Wagner³, Marie Grace⁴, Emma Rosenbluth^1 2, Clara Rodriquez-Rivas^1 2, Hernis de la Cruz⁵, Jessica Overbey⁵, Rhoda Sperling^2 6

12.

Electronic Health Record Reminder Effect on Hepatitis C Antibody Screening

J Am Board Fam Med. Nov-Dec 2020;33(6):1016-1019. doi: 10.3122/jabfm.2020.06.190440.

Elie Mulhem¹, Indigo Brown¹, Ke Song¹

13.

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

J Hepatol. 2020 Nov 18;S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017.Online ahead of print.

Julia Dietz¹, Velia Chiara Di Maio², Adolfo de Salazar³, Dolores Merino⁴, Johannes Vermehren¹, Stefania Paolucci⁵, Andreas E Kremer⁶, Magdalena Lara⁷, Maria Rodriguez Pardo⁸, Heinz Zoller⁹, Elisabetta Degasperi¹⁰, Kai-Henrik Peiffer¹, Laura Sighinolfi¹¹, Francisco Téllez¹², Christiana Graf¹, Valeria Ghisetti¹³, Jonas Schreiber¹⁴, Elisa Fernández-Fuertes¹⁵, Lucio Boglione¹⁶, Leopoldo Muñoz-Medina¹⁷, Rudolf Stauber¹⁸, William Gennari¹⁹, Blanca Figueruela²⁰, Jesús Santos²¹, Pietro Lampertico¹⁰, Stefan Zeuzem¹, Francesca Ceccherini-Silberstein², Federico García³, Christoph Sarrazin²²

14.

Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017

Am J Prev Med. 2020 Nov 18;S0749-3797(20)30435-9. doi: 10.1016/j.amepre.2020.08.031.Online ahead of print.

Ping Du¹, Xi Wang², Lan Kong², Thomas Riley 3rd³, Jeah Jung⁴

15.

Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs

Subst Use Misuse. 2020 Nov 18;1-10. doi: 10.1080/10826084.2020.1846198.Online ahead of print.

Leith Morris¹, Linda Selvey¹, Owain Williams¹, Charles Gilks¹, Andrew Smirnov^1 2

16.

Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs

Drug Alcohol Rev. 2020 Nov 8. doi: 10.1111/dar.13198. Online ahead of print.

Vivian D Hope¹, James McVeigh², Emma Begley¹, Rachel Glass³, Claire Edmundson³, Ellen Heinsbroek³, Joseph Kean⁴, John Campbell⁵, Mark Whitfield¹, Gareth Morgan⁶, Dean Acreman⁷, Josie Smith⁷

17.

Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation

BMC Nephrol. 2020 Nov 10;21(1):473. doi: 10.1186/s12882-020-02114-y.

Gretchen C Edwards¹, Maren E Shipe², Lindsay Smith³, Christianna Gamble³, David Shaffer⁴, Beatrice P Concepcion⁵, Rachel Forbes⁴

18.

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.

Nicholas Lim¹, Dupinder Singh¹, Scott Jackson², John R Lake¹

19.

Routine Screening and Linkage to Care for Hepatitis C Virus in an Urban Safety-Net Health System, 2017-2019

Public Health Rep. 2020 Nov 11;33354920969179. doi: 10.1177/0033354920969179.Online ahead of print.

Bijou R Hunt¹, Christopher Ahmed¹, Kimberly Ramirez-Mercado¹, Christopher Patron¹, Nancy R Glick^1 2

20.

Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C Treated Liver Transplant Recipients with Residual Fibrosis or Cirrhosis

Liver Transpl. 2020 Nov 8. doi: 10.1002/lt.25934. Online ahead of print.

Ethan W Weinberg¹, Michael P Curry², Catherine T Frenette³, Fredric G Regenstein⁴, Eugene R Schiff⁵, Zachary D Goodman⁶, James Mac Robinson⁷, Jean L Chan⁷, Joanne C Imperial⁷, K Rajender Reddy¹

21.

Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV

J Infect Dis. 2020 Nov 3;jiaa686. doi: 10.1093/infdis/jiaa686. Online ahead of print.

Danielle F Haley¹, Andrew Edmonds², Catalina Ramirez³, Audrey L French⁴, Phyllis Tien⁵, Chloe L Thio⁶, Mallory D Witt⁷, Eric C Seaberg⁸, Michael W Plankey⁹, Mardge H Cohen¹⁰, Adaora A Adimora¹¹

22.

Estimating the Year Each State in the United States Will Achieve the World Health Organization

Adv Ther. 2020 Nov 3;1-18. doi: 10.1007/s12325-020-01535-3. Online ahead of print.

Mark Sulkowski¹, Wei-Han Cheng², Steven Marx², Yuri Sanchez Gonzalez², John Strezewski², Nancy Reau³

23.

The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017

EClinicalMedicine. 2020 Oct 5;27:100567. doi: 10.1016/j.eclinm.2020.100567.eCollection 2020 Oct.

Justin Chan¹, Fatos Kaba¹, Jessie Schwartz², Angelica Bocour², Matthew J Akiyama³, Zachary Rosner¹, Ann Winters², Patricia Yang¹, Ross MacDonald¹

24.

PERCEPTIONS OF NETWORK BASED RECRUITMENT FOR HEPATITIS C TESTING AND TREATMENT AMONG PERSONS WHO INJECT DRUGS: A QUALITATIVE EXPLORATION

Int J Drug Policy. 2020 Nov 4;88:103019. doi: 10.1016/j.drugpo.2020.103019.Online ahead of print.

Kathleen M Ward¹, Sean D McCormick², Mark Sulkowski³, Carl Latkin⁴, Geetanjali Chander⁵, Oluwaseun Falade-Nwulia⁶

25.

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

BMC Infect Dis. 2020 Oct 29;20(1):802. doi: 10.1186/s12879-020-05531-4.

Jessica Ramsay¹, Julie Marsh¹, Alisa Pedrana^2 3, Nada Andric⁴, Richard Norman⁵, Wendy Cheng^6 7 8, Steve Webb^3 9, Nikolajs Zeps¹⁰, Matthew Bellgard¹¹, Todd Graves¹², Margaret Hellard^{2 3 13 14 15}, Tom Snelling^{16 17 18 19 20}

26.

Early Outcomes of Multivisceral Transplant using Hepatitis C Positive Donors

Ann Thorac Surg. 2020 Oct 26;S0003-4975(20)31736-7. doi: 10.1016/j.athoracsur.2020.08.044.Online ahead of print.

William G McMaster Jr¹, Zakiur M Rahaman², Maren E Shipe³, Eric N Quintana⁴, Emily M Sandhaus⁵, Sarah S Smith⁶, Jerod E Crockett⁷, Rachel C Forbes⁸, Kelly H Schlendorf⁹, Ashish S Shah¹⁰

27.

Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents

Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa377. doi: 10.1093/ofid/ofaa377.eCollection 2020 Oct.

Brianna L Norton¹, Matthew J Akiyama¹, Linda Agyemang¹, Moonseong Heo², Irene- Pericot-Valverde³, Alain H Litwin^3 4 5

28.

Immune system control of hepatitis C virus infection

Curr Opin Virol. 2020 Oct 30;46:36-44. doi: 10.1016/j.coviro.2020.10.002.Online ahead of print.

Johnasha D Stuart¹, Eduardo Salinas¹, Arash Grakoui²

29.

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care

Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa263. doi: 10.1093/ofid/ofaa263.eCollection 2020 Jul.

Justin Chan¹, Jessie Schwartz², Fatos Kaba¹, Angelica Bocour², Matthew J Akiyama^1 3, Laura Hobstetter¹, Zachary Rosner¹, Ann Winters², Patricia Yang¹, Ross MacDonald¹

30.

The use of organs from hepatitis C virus-viremic donors into uninfected recipients

Curr Opin Organ Transplant. 2020 Dec;25(6):620-625. doi: 10.1097/MOT.0000000000000826.

Jeffrey A Kahn¹

31.

Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation

Int J Drug Policy. 2020 Oct 12;86:102964. doi: 10.1016/j.drugpo.2020.102964.Online ahead of print.

Alison D Marshall¹, Max Hopwood², Jason Grebely³, Carla Treloar²

32.

Sustained Sobriety: A Qualitative Study of Persons with HIV and Chronic Hepatitis C Coinfection and a History of Problematic Drinking

AIDS Behav. 2020 Oct 16. doi: 10.1007/s10461-020-03067-x. Online ahead of print.

Abigail Howell¹, Audrey Lambert^2 3, Megan M Pinkston⁴, Claire E Blevins⁴, Jumi Hayaki⁵, Debra S Herman⁴, Ethan Moitra⁴, Michael D Stein³, H Nina Kim⁶

33.

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents

J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCTH.2020.00034.Epub 2020 Jul 30.

Jenny Hong¹, Robert C Wright¹, Nilu Partovi^1 2, Eric M Yoshida^3 4, Trana Hussaini^1 2 3

34.

Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination

SN Compr Clin Med. 2020 Oct 18;1-8. doi: 10.1007/s42399-020-00588-3.Online ahead of print.

Cristina Stasi^1 2, Caterina Silvestri¹, Fabio Voller¹

35.

Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV

mSystems. 2020 Oct 13;5(5):e00528-20. doi: 10.1128/mSystems.00528-20.

Bryn C Taylor^# 1, Kelly C Weldon^# 2 3, Ronald J Ellis^4 5, Donald Franklin⁶, Daniel McDonald⁷, Gregory Humphrey⁷, MacKenzie Bryant⁷, Julia Toronczak⁷, Tara Schwartz⁷, Jennifer Iudicello⁶, Robert Heaton⁶, Igor Grant⁶, Sara Gianella⁸

36.

Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply

J Stud Alcohol Drugs. 2020 Sep;81(5):556-560.

Matthew Bonn¹, Adam Palayew², Sofia Bartlett³, Thomas D Brothers⁴, Natasha Touesnard¹, Mark Tyndall⁵

37.

Management of Hepatitis C in Children and Adolescents

J Pediatric Infect Dis Soc. 2020 Oct 12;piaa114. doi: 10.1093/jpids/piaa114. Online ahead of print.

Victoria A Statler¹, Claudia Espinosa²

38.

Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature

Gastroenterol Nurs. Sep/Oct 2020;43(5):E172-E183. doi: 10.1097/SGA.0000000000000488.

Donald E Bailey Jr¹, Donna M Zucker

39.

The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting

Addiction. 2020 Oct 2. doi: 10.1111/add.15277. Online ahead of print.

Lise Lafferty¹, Jake Rance¹, Gregory J Dore², Andrew R Lloyd², Carla Treloar¹

40.

Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®

Pharmacoecon Open. 2020 Sep 30. doi: 10.1007/s41669-020-00232-9. Online ahead of print.

T Joseph Mattingly 2nd¹, Karen Li², Arnold Ng², Tieu-Long Ton-Nu², Jennifer Owens³

41.

Escape from planned obsolescence: Hepatitis C, the cirrhotic liver, and clonal expansions

J Exp Med. 2020 Mar 2;217(3):e20191070. doi: 10.1084/jem.20191070.

Andrea D Branch¹

42.

T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine

J Hepatol. 2020 Sep 28;S0168-8278(20)33665-5. doi: 10.1016/j.jhep.2020.09.022.Online ahead of print.

Robert Thimme¹

43.

Characteristics of Adults With Hepatitis C Virus: Evidence From the National Health and Nutrition Examination Survey 2011-2012

Gastroenterol Nurs. Sep/Oct 2020;43(5):363-374. doi: 10.1097/SGA.0000000000000459.

Sheila A Williams¹, Lisa C Lindley

44.

Misclassification Error-Adjusted Prevalence of Injection Drug Use Among Infective Endocarditis Hospitalizations in the United States: A Serial Cross-Sectional Analysis of the 2007-2016 National Inpatient Sample

Am J Epidemiol. 2020 Sep 30;kwaa207. doi: 10.1093/aje/kwaa207. Online ahead of print.

Kaitlin M McGrew¹, Tabitha Garwe¹, S Reza Jafarzadeh², Douglas A Drevets^3 4, Yan Daniel Zhao¹, Mary B Williams^1 5, Hélène Carabin^1 6 7 8

45.

EASL recommendations on treatment of hepatitis C: Final update of the series

J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018.Epub 2020 Sep 15.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:

46.

In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent

Clin Gastroenterol Hepatol. 2020 Sep 21;S1542-3565(20)31294-5.doi: 10.1016/j.cgh.2020.09.033. Online ahead of print.

Therese Bittermann¹, K Rajender Reddy²

47.

Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection

J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408. Online ahead of print.

Philip J Johnson¹, Sarah Berhane¹, Alex J Walker², Fiona H Gordon³, Steven D Ryder^4 5, Stuart McPherson⁶, Aravamuthan Sreedharan⁷, Andrew A Ustianowski⁸, Kosh Agarwal⁹, David Mutimer¹⁰, Takeshi Kumada¹¹, Hidenori Toyoda¹², William L Irving⁵, HCV Research UK

48.

Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome

mSystems. 2020 Sep 29;5(5):e00465-20. doi: 10.1128/mSystems.00465-20.

Bryn C Taylor¹, Kelly C Weldon^2 3, Ronald J Ellis^4 5, Donald Franklin⁶, Tobin Groth⁷, Emily C Gentry², Anupriya Tripathi^2 7 8, Daniel McDonald⁸, Gregory Humphrey⁸, MacKenzie Bryant⁸, Julia Toronczak⁸, Tara Schwartz⁸, Michelli F Oliveira⁹, Robert Heaton⁶, Igor Grant⁶, Sara Gianella¹⁰, Scott Letendre^9 11, Austin Swafford³, Pieter C Dorrestein^2 3 8, Rob Knight^{12 8 13 14}

49.

Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City

J Public Health Manag Pract. 2020 Sep 9. doi: 10.1097/PHH.0000000000001150.Online ahead of print.

Kevin Guerra¹, Angelica Bocour, Miranda S Moore, Ann Winters

50.

Protocol for a systematic review of treatment adherence for HIV, hepatitis C and tuberculosis among homeless populations

Syst Rev. 2020 Sep 13;9(1):211. doi: 10.1186/s13643-020-01470-y.

Luke Johnson^1 2, Dan Lewer³, Robert W Aldridge⁴, Andrew C Hayward¹, Alistair Story¹

51.

The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data

Adv Ther. 2020 Nov;37(11):4709-4719. doi: 10.1007/s12325-020-01492-x. Epub 2020 Sep 14.

Mark Sulkowski¹, Raluca Ionescu-Ittu², Dendy Macaulay³, Yuri Sanchez-Gonzalez⁴

52.

Hepatitis C virus infections among people aged 15-44, United States, 2009-2018

Public Health Nurs. 2020 Sep 15. doi: 10.1111/phn.12808. Online ahead of print.

Theresa Watts¹, Diane Lauver², Ajay K Sethi³, Traci Snedden², Susan Zahner²

53.

Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs?

Can J Public Health. 2020 Sep 16. doi: 10.17269/s41997-020-00413-3. Online ahead of print.

Jessica Jacob^1 2, Lianping Ti^1 2, Rod Knight^3 4

54.

Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic

Infect Dis Ther. 2020 Sep 11. doi: 10.1007/s40121-020-00335-0.Online ahead of print.

Jessica F Jones¹, Jamie Legaspi², Eric Chen², Kelly Lee³, Jennifer Le³

55.

Retreatment of Hepatitis C Infection With Direct-Acting Antivirals

Fed Pract. 2020 Jul;37(7):316-319.

Marisel Segarra-Newnham¹, Nathalie See¹, Gail Fox-Seaman¹

56.

Selecting a theoretical framework to explore the social and cognitive uncertainty that hepatitis C treatment represents for people who inject drugs

Appl Nurs Res. 2020 Aug 3;151339. doi: 10.1016/j.apnr.2020.151339. Online ahead of print.

Greg Carlson¹, Tracy E Crane², Ruth E Taylor-Piliae³

57.

Cholesterol sensing by CD81 is important for hepatitis C virus entry

J Biol Chem. 2020 Sep 8;jbc.RA120.014761. doi: 10.1074/jbc.RA120.014761.Online ahead of print.

Machaela Palor¹, Lenka Stejskal¹, Piya Mandal¹, Annasara Lenman², Maria Pia Alberione³, Jared Kirui⁴, Rebecca Moeller⁴, Stefan Ebner⁵, Felix Meissner⁵, Gisa Gerold⁶, Adrian J Shepherd⁷, Joe Grove¹

58.

Housing Stability and Hepatitis C Infection for Young Adults Who Inject Drugs: Examining the Relationship of Consistent and Intermittent Housing Status on HCV Infection Risk

J Urban Health. 2020 Sep 8. doi: 10.1007/s11524-020-00445-7. Online ahead of print.

Meghan D Morris¹, Irene H Yen², Steve Shiboski³, Jennifer L Evans³, Kimberly Page⁴

59.

Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update

J Arthroplasty. 2020 Aug 18;S0883-5403(20)30909-8. doi: 10.1016/j.arth.2020.08.023.Online ahead of print.

Cdr Bennett H Shapiro¹, Ramsey C Cheung², Nicholas J Giori³

60.

Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City

J Infect Dis. 2020 Sep 2;222(Supplement_5):S322-S334. doi: 10.1093/infdis/jiz659.

Ashly E Jordan^1 2 3, Charles M Cleland^2 4, Katarzyna Wyka¹, Bruce R Schackman⁵, David C Perlman^2 6, Denis Nash¹

61.

Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017

Public Health Rep. 2020 Sep 4;33354920952068. doi: 10.1177/0033354920952068.Online ahead of print.

Rachel Webster¹, Miranda S Moore¹, Angelica Bocour¹, Nirah Johnson¹, Ann Winters¹

62.

Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood

J Pediatr. 2020 Sep 2;S0022-3476(20)31124-0. doi: 10.1016/j.jpeds.2020.08.088.Online ahead of print.

Emma Greenaway¹, Alexander Haines², Simon C Ling³, Murray Krahn⁴

63.

Comparing direct acting antivirals for hepatitis C using observational data - Why and how?

Pharmacol Res Perspect. 2020 Oct;8(5):e00650. doi: 10.1002/prp2.650.

Jim Young^1 2 3, Stanley Wong^4 5, Naveed Z Janjua^4 5, Marina B Klein^1 2 6

64.

Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon

J Gen Virol. 2020 Sep 8. doi: 10.1099/jgv.0.001486. Online ahead of print.

Joseph C Ward¹, Sebastian Bowyer¹, Shucheng Chen¹, Guilherme Rodrigues Fernandes Campos^2 1, Santseharay Ramirez^3 4, Jens Bukh^3 4, Mark Harris¹

65.

Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System

Open Forum Infect Dis. 2020 Aug 7;7(8):ofaa322. doi: 10.1093/ofid/ofaa322.eCollection 2020 Aug.

Shane W Reader¹, Hyun-Seok Kim², Hashem B El-Serag², Aaron P Thrift¹

66.

Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or

J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393. Online ahead of print.

David Stephen Prince^1 2, Joseph Louis Pipicella^1 3, Melissa Fraser¹, Frank Alvaro^1 4, Michael Maley^1 2 4, Hong Foo^1 4 5, Paul MacConachie Middleton^{1 2 3 6 7}, Scott Anthony Davison^1 2, Greg John Dore⁸, Geoff William McCaughan^7 9, Miriam Tania Levy^1 2 3

67.	Hepatitis C Virus
	Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48. doi: 10.7326/AITC202009010.

68.

Late presenters among minority patients with chronic hepatitis C infection in the USA

Int J Public Health. 2020 Sep;65(7):1181-1191. doi: 10.1007/s00038-020-01467-3.Epub 2020 Aug 29.

Calvin Q Pan^1 2, Charles Rabinovich³, Vijay Gayam⁴, Milana Normatov³, Bazhena Fidman³, Dan Wang⁵

69.

Rates and Characteristics of SARS-CoV-2 Infection in Persons with Hepatitis C Virus Infection

Liver Int. 2020 Oct 2. doi: 10.1111/liv.14681. Online ahead of print.

Adeel A Butt^1 2 3, Peng Yan¹

70.

Hepatic benefits of HCV cure

J Hepatol. 2020 Aug 7;S0168-8278(20)30530-4. doi: 10.1016/j.jhep.2020.08.006.Online ahead of print.

Vincenza Calvaruso¹, Antonio Craxì²

71.

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814.

Daniel H Leung¹, James E Squires², Ravi Jhaveri³, Nanda Kerkar⁴, Chuan-Hao Lin⁵, Parvathi Mohan⁶, Karen F Murray⁷, Regino P Gonzalez-Peralta⁸, Eve A Roberts⁹, Shikha S Sundaram¹⁰

72.

Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C

BMJ Open Gastroenterol. 2020 Aug;7(1):e000470. doi: 10.1136/bmjgast-2020-000470.

Stuart McPherson^1 2, Shion Gosrani³, Sarah Hogg³, Preya Patel³, Aaron Wetten³, Rachael Welton³, Kate Hallsworth^3 2, Matthew Campbell^4 5

73.

Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play

Semin Liver Dis. 2020 Aug 26. doi: 10.1055/s-0040-1716343. Online ahead of print.

Fabienne Marcellin¹, Antoine Jaquet^2 3, Jeffrey V Lazarus⁴, Patricia Molina⁵, Patrizia Carrieri¹

74.

Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients

Am J Transplant. 2020 Aug 10. doi: 10.1111/ajt.16245. Online ahead of print.

Cathy Logan¹, Ily Yumul², Javier Cepeda¹, Victor Pretorius³, Eric Adler⁴, Saima Aslam¹, Natasha K Martin^1 5

75.

Identification of Risk Factors for Testing of Hepatitis C in Non-Birth Cohort Patients: Is Universal Screening Necessary?

J Addict Med. 2020 Jul 20. doi: 10.1097/ADM.0000000000000702. Online ahead of print.

Amanda Smart¹, Alexander Geboy, Peter Basch, Whitney Nichols, Alexander Zeymo, Idene Perez, Maria Hafeez, Ilan Fleisher, Stephen Fernandez, Dawn Fishbein

76.

A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment

Kidney Med. 2019 Jul 11;1(4):200-206. doi: 10.1016/j.xkme.2019.06.003.eCollection Jul-Aug 2019.

Nerissa George¹, AnnMarie Liapakis², Kevin M Korenblat³, Tingting Li⁴, David Roth⁵, Jerry Yee⁶, Kevin J Fowler⁷, Lehman Howard⁸, Jingxia Liu¹, Mary C Politi¹

77.

Identifying ED patients with previous abnormal HIV or hepatitis C test results who may require additional services

Am J Emerg Med. 2020 May 11;38(9):1831-1833. doi: 10.1016/j.ajem.2020.05.020.Online ahead of print.

Andrew H Ruffner¹, Rachel M Ancona², Catherine Hamilton³, Francisco J Fernandez⁴, Kiran A Faryar⁵, Bennett H Lane⁶, Michael S Lyons⁷

78.

Pharmacology Update for the Treatment of Hepatitis C Virus

Nurs Clin North Am. 2020 Sep;55(3):347-359.doi: 10.1016/j.cnur.2020.06.008.Epub 2020 Jul 16.

Leslie Hopkins¹, Travis Dunlap², Holly Cline²

79.

Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis

Int J Drug Policy. 2020 Jul 27;84:102875. doi: 10.1016/j.drugpo.2020.102875.Online ahead of print.

Tyler S Bartholomew¹, Hansel E Tookes², David P Serota², Czarina N Behrends³, David W Forrest⁴, Daniel J Feaster⁵

80.

Screening for Hepatitis C Virus: How Universal Is Universal?

Clin Ther. 2020 Jul 22;S0149-2918(20)30322-2. doi: 10.1016/j.clinthera.2020.06.012.Online ahead of print.

Ravi Jhaveri¹

81.

Simplification of Care for Chronic Hepatitis C Virus Infection

Semin Liver Dis. 2020 Jul 28.doi: 10.1055/s-0040-1713657. Online ahead of print.

Jean-Michel Pawlotsky¹, Christian B Ramers², John F Dillon³, Jordan J Feld⁴, Jeffrey V Lazarus⁵

82.

A model of the economic benefits of global hepatitis C elimination: an investment case

Lancet Gastroenterol Hepatol. 2020 Jul 27;S2468-1253(20)30008-X.

doi: 10.1016/S2468-1253(20)30008-X. Online ahead of print.

Nick Scott¹, Christian Kuschel², Alisa Pedrana³, Sophia Schroeder³, Jessica Howell⁴, Alexander Thompson⁵, David P Wilson³, Margaret Hellard⁶

83.

Global hepatitis C elimination: an investment framework

Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.

Alisa Pedrana¹, Jessica Howell², Nick Scott³, Sophia Schroeder³, Christian Kuschel⁴, Jeffrey V Lazarus⁵, Rifat Atun⁶, Ricardo Baptista-Leite⁷, Ellen 't Hoen⁸, Sharon J Hutchinson⁹, Lisa Aufegger¹⁰, Raquel Peck¹¹, Annette H Sohn¹², Tracy Swan¹³, Mark Thursz¹⁴, Olufunmilayo Lesi¹⁵, Manik Sharma¹⁶, John Thwaites¹⁷, David P Wilson³, Margaret Hellard¹⁸

84.

Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020 MMWR

Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.

MMWR Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.

Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, Carolyn Chu, David Kuhar, David K Henderson, Susanna Naggie, Saleem Kamili, Philip R Spradling, Stuart C Gordon, Mark B Russi, Eyasu H Teshale

85.

Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy

Int J Drug Policy. 2020 Jul 6;83:102837. doi: 10.1016/j.drugpo.2020.102837.Online ahead of print.

Jenny Iversen¹, Gregory J Dore², Mitchell Starr³, Beth Catlett⁴, Philip Cunningham³, Louise Geddes², Lisa Maher²

86.

Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies

Gastroenterol Nurs. Jul/Aug 2020;43(4):303-309. doi: 10.1097/SGA.0000000000000458.

Jacqueline A Richmond¹, Lesley Gallagher, Lucy McDonald, Margaret O'Sullivan, Christine Fitzsimmons, Alisa Pedrana

87.

Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas

Open Forum Infect Dis. 2020 Jun 2;7(7):ofaa191. doi: 10.1093/ofid/ofaa191. eCollection 2020 Jul.

Hyun-Seok Kim¹, Rosalia Guerrero², Shane W Reader³, Maria Daheri⁴, Maya Balakrishnan¹, Catherine L Troisi², Hashem B El-Serag¹, Aaron P Thrift^3 5

88.

Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics

PLoS One. 2020 Jul 9;15(7):e0235778. doi: 10.1371/journal.pone.0235778. eCollection 2020.

Dagan Coppock¹, Edgar Chou², Edward Gracely³, Robert Gross⁴, Dong Heun-Lee¹

89.

Post-transplant survey to assess patient experiences with donor-derived HCV infection

Transpl Infect Dis. 2020 Jul 7;e13402. doi: 10.1111/tid.13402. Online ahead of print.

Katya Prakash¹, Claudia Ramirez-Sanchez¹, Sydney I Ramirez¹, Cathy Logan¹, Nancy Law¹, Kristin Mekeel², Victor Pretorius², Saima Aslam¹

90.

Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience

Transplant Proc. 2020 Jul 4;S0041-1345(20)32581-1. doi:10.1016/j.transproceed.2020.06.005.Online ahead of print.

Eloi Chevallier¹, Matthias Büchler², Sophie Caillard³, Nicolas Bouvier⁴, Charlotte Colosio⁵, Joseph Rivalan⁶, Johnny Sayegh⁷, Dominique Bertrand⁸, Yannick Le Meur⁹, Antoine Thierry¹⁰, Cyril Garrouste¹¹, Jean-Philippe Rerolle¹², Lionel Rostaing¹³, Philippe Gatault²

91.

Fibrosis improvement in patients with HCV treated with direct-acting antivirals

Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.Online ahead of print.

James McPhail¹, Omar T Sims^{2 3 4 5 6}, Yuqi Guo⁷, David Wooten¹, John S Herndon¹, Omar I Massoud⁸

92.

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions

Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.

Julia Dietz¹, Johannes Vermehren¹, Katrin Matschenz², Peter Buggisch², Hartwig Klinker³, Julian Schulze Zur Wiesch⁴, Holger Hinrichsen⁵, Kai-Henrik Peiffer¹, Christiana Graf¹, Thomas Discher⁶, Janina Trauth⁶, Jörn M Schattenberg⁷, Felix Piecha⁴, Stefan Mauss⁸, Claus Niederau⁹, Tobias Müller¹⁰, Christoph Neumann-Haefelin¹¹, Christoph P Berg¹², Stefan Zeuzem¹, Christoph Sarrazin^1 13, European HCV Resistance Study Group

93.

Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data

Public Health Rep. Jul/Aug 2020;135(4):461-471. doi: 10.1177/0033354920937284.Epub 2020 Jul 7.

Mary E Evans^1 2 3, Marissa Person⁴, Brigg Reilley⁵, Jessica Leston⁵, Richard Haverkate⁶, Jeffrey T McCollum⁶, Andria Apostolou^6 7, Michele K Bohm¹, Michelle Van Handel⁸, Danae Bixler⁹, Andrew J Mitsch², Dana L Haberling⁴, Sarah M Hatcher^3 5, Thomas Weiser¹⁰, Kim Elmore², Eyasu H Teshale⁹, Paul J Weidle², Philip J Peters², Kate Buchacz²

94.

The Inflammatory Relationship between Hepatitis C Virus with Coronary and Carotid Atherosclerosis

Cardiol Rev. 2020 Jun 18. doi: 10.1097/CRD.0000000000000314. Online ahead of print.

Michael Broker¹, Shalom Z Frager², Nayan S Patel³, Edward Lebovics², William H Frishman¹

95.

Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions

Am J Gastroenterol. 2020 Jul;115(7):1022-1023.doi: 10.14309/ajg.0000000000000649.

Nathalie Pena Polanco¹, David Goldberg¹

96.

Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors

Semin Thorac Cardiovasc Surg. 2020 Jul 2;S1043-0679(20)30236-7.doi: 10.1053/j.semtcvs.2020.06.045. Online ahead of print.

Deane E Smith¹, Stacey Chen², Anthony Fargnoli¹, Tyler Lewis³, Aubrey C Galloway¹, Zachary N Kon¹, Nader Moazami¹

97.

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Clin Gastroenterol Hepatol. 2020 Jul 1;S1542-3565(20)30907-1. doi: 10.1016/j.cgh.2020.06.044.Online ahead of print.

Eli Zuckerman¹, Julio A Gutierrez², Douglas E Dylla³, Victor de Ledinghen⁴, Andrew J Muir⁵, Michael Gschwantler⁶, Massimo Puoti⁷, Florin Caruntu⁸, Jihad Slim⁹, Frederik Nevens¹⁰, Samuel Sigal¹¹, Stanley Cohen¹², Linda M Fredrick³, Ana Gabriela Pires Dos Santos³, Lino Rodrigues Jr³, John F Dillon¹³

98.

Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals

Int J Antimicrob Agents. 2020 Jun 26;106067. doi: 10.1016/j.ijantimicag.2020.106067.Online ahead of print.

M Pisaturo¹, M Starace¹, C Minichini¹, S De Pascalis², L Occhiello¹, A Di Fraia¹, V Messina³, V Sangiovanni⁴, E Claar⁵, N Coppola⁶, CampC Network

99.

Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study

J Cancer Educ. 2020 Jun 25. doi: 10.1007/s13187-020-01805-2. Online ahead of print.

Bertha E Flores¹, Andrea A Fernandez¹, Chen-Pin Wang^2 3, Raudel Bobadilla³, Ludivina Hernandez³, Mamta K Jain⁴, Barbara J Turner⁵

100.

Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention

Drug Alcohol Depend. 2020 Jun 12;213:108116. doi: 10.1016/j.drugalcdep.2020.108116.Online ahead of print.

Brooke Severe¹, Jeanette M Tetrault², Lynn Madden², Robert Heimer³

101.

Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data

Sci Rep. 2020 Jun 29;10(1):10521. doi: 10.1038/s41598-020-67013-6.

Orla M Doyle¹, Nadejda Leavitt², John A Rigg³

102.

The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services

PLoS One. 2020 Jun 30;15(6):e0235445.doi: 10.1371/journal.pone.0235445. eCollection 2020.

Michael W Traeger^1 2, Alisa E Pedrana^1 2, Daniela K van Santen^1 2, Joseph S Doyle^1 3, Jessica Howell^1 4, Alexander J Thompson⁴, Carol El-Hayek¹, Jason Asselin¹, Victoria Polkinghorne¹, Dean Membrey⁵, Fran Bramwell⁵, Allison Carter⁶, Rebecca Guy⁶, Mark A Stoové^1 2 7, Margaret E Hellard^1 2 3, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)

103.

Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care

PLoS One. 2020 Jun 17;15(6):e0234577.doi: 10.1371/journal.pone.0234577. eCollection 2020.

David Brain^1 2, Jonathan Mitchell^3 4, James O'Beirne^3 4

104.

Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL

Harm Reduct J. 2020 Jun 10;17(1):40. doi: 10.1186/s12954-020-00385-0.

Tyler S Bartholomew¹, Jason Onugha¹, Corinne Bullock¹, Carolina Scaramutti¹, Hardik Patel¹, David W Forrest², Daniel J Feaster¹, Hansel E Tookes³

105.

Hepatitis C cascade of care at an integrated community facility for people who inject drugs

J Subst Abuse Treat. 2020 Jul;114:108025. doi: 10.1016/j.jsat.2020.108025. Epub 2020 May 4.

Leith Morris¹, Linda Selvey², Owain Williams², Charles Gilks², Amanda Kvassy³, Andrew Smirnov⁴

106.

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study

Lancet Gastroenterol Hepatol. 2020 Jun 9;S2468-1253(19)30417-0.doi: 10.1016/S2468-1253(19)30417-0. Online ahead of print.

Eric Lawitz¹, Charles S Landis², Steven L Flamm³, Maurizio Bonacini⁴, Grisell Ortiz-Lasanta⁵, Jonathan Huang⁶, Jie Zhang⁷, Brian J Kirby⁷, Shampa De-Oertel⁷, Robert H Hyland⁷, Anu O Osinusi⁷, Diana M Brainard⁷, Richard Robson⁸, Benedict J Maliakkal⁶, Stuart C Gordon⁹, Edward J Gane¹⁰

107.

Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review

Pharmacoeconomics. 2020 Jun 12. doi: 10.1007/s40273-020-00933-3.Online ahead of print.

T Joseph Mattingly 2nd¹, Bryan L Love², Bilal Khokhar³

108.

Hepatitis C and Treatment in Patients with Chronic Kidney Disease

Dis Mon. 2020 Jun 15;101017. doi: 10.1016/j.disamonth.2020.101017.Online ahead of print.

Abhijay Jalota¹, Brian K Lindner², Beje Thomas³, Edgar V Lerma⁴

109.

Glycemic Control after Initiating Direct-Acting Antiviral Agents in Patients with Hepatitis C Virus and Type 2 Diabetes Mellitus Using the United States Integrated Healthcare System

J Res Pharm Pract. 2020 Mar 28;9(1):16-23. doi: 10.4103/jrpp.JRPP_19_110.eCollection Jan-Mar 2020.

Alicia Halim Wong¹, John Sie¹, Angela Chen¹, Basuki Gunawan², Joanie Chung³, Nazia Rashid⁴

110.

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

Hepatol Commun. 2020 Apr 6;4(6):904-915. doi: 10.1002/hep4.1496. eCollection 2020 Jun.

Mark W Douglas^1 2 3, Enoch S E Tay^1 4, Dao Sen Wang¹, Adrian T L Ong^1 2, Caroline Wilson¹, Amy Phu¹, Jen Kok⁴, Dominic E Dwyer^3 4, Rowena A Bull⁵, Andrew R Lloyd⁵, Tanya L Applegate⁵, Gregory J Dore⁵, Anita Y Howe⁶, Richard Harrigan⁷, Jacob George^1 3

111.

Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection

Am J Case Rep. 2020 Jun 4;21:e923326. doi: 10.12659/AJCR.923326.

Joshua P Havens^1 2, Nichole N Regan¹, Sara H Bares¹

112.

High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department

PLoS One. 2020 Jun 4;15(6):e0233927. doi: 10.1371/journal.pone.0233927. eCollection 2020.

Erik S Anderson¹, Carly Russell¹, Kellie Basham¹, Martha Montgomery¹, Helen Lozier¹, Abigail Crocker¹, Marisa Zuluaga¹, Douglas A E White¹

113.

Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis

Oncologist. 2020 Jun 2. doi: 10.1634/theoncologist.2020-0172. Online ahead of print.

Saptaparni Ghosh¹, Minghua L Chen², Janice Weinberg³, Tsion Fikre⁴, Naomi Y Ko⁴

114.

Pretreatment Assessment of Psychosocial Readiness Is Not Associated with Improved Treatment Outcomes in a Safety-Net HCV Treatment Clinic

South Med J. 2020 Jun;113(6):261-266.doi: 10.14423/SMJ.0000000000001099.

Zoë Kopp¹, Lesley Miller¹, Sara Turbow¹

115.

Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007-2016

South Med J. 2020 Jun;113(6):298-304. doi: 10.14423/SMJ.0000000000001104.

Charlene Siza¹, Danae Bixler¹, Sherri Davidson¹

116.

How do people in prison feel about opt-out hepatitis C virus testing?

J Viral Hepat. 2020 Jun 2.doi: 10.1111/jvh.13338. Online ahead of print.

Kathryn Jack¹, Paul Linsley², Brian James Thomson¹, William Lucien Irving¹

117.

Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction

Sci Rep. 2020 Jul 24;10(1):12440. doi: 10.1038/s41598-020-69013-y.

Alexandria Miller¹, Jennifer McNamara², Scott L Hummel^2 3, Matthew C Konerman², Monica A Tincopa⁴

118.

Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents

R I Med J (2013). 2020 Jun 1;103(5):35-40.

Alyssa K Francis¹, Francesca L Beaudoin², Safiya S Naidjate³, Christine Berard-Collins⁴, Andrew R Zullo⁵

119.

Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions

J Am Board Fam Med. May-Jun 2020;33(3):407-416. doi: 10.3122/jabfm.2020.03.190305.

Thomas Ludden¹, Lindsay Shade², Jeremy Thomas², Brisa Urquieta de Hernandez², Sveta Mohanan², Mark W Russo², Michael Leonard², Philippe J Zamor², Charity G Patterson², Hazel Tapp²

120.

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a

Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25.

Philip Rosenthal¹, Michael R Narkewicz², Betty B Yao³, Christopher D Jolley⁴, Steven J Lobritto⁵, Jessica Wen⁶, Jean P Molleston⁷, Evelyn K Hsu⁸, Maureen M Jonas⁹, Jiuhong Zha³, Li Liu³, Daniel H Leung¹⁰

121.

Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype

J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337. Online ahead of print.

Kevin G Pollock¹, Scott A McDonald², Rory Gunson³, Allan McLeod⁴, April Went⁴, David J Goldberg³, Sharon J Hutchinson³, Stephen T Barclay^1 5

122.	Direct acting antiviral HCV treatment does not influence renal function
	Matt Driedger¹, Chrissi Galanakis², Curtis Cooper¹

123.

Public Health Clinic-Based Hepatitis C Treatment

Am J Prev Med. 2020 May 16;S0749-3797(20)30146-X. doi:10.1016/j.amepre.2020.03.006.Online ahead of print.

Amanda M Rosecrans¹, Aneesha Cheedalla², Sarah T Rives³, Lisa A Scotti³, Robert E Harris³, Adena H Greenbaum⁴, Risha R Irvin², Boatemaa A Ntiri-Reid⁵, Holly T Brown³, Karen E Alston³, Jaeson A Smith⁴, Kathleen R Page³, Oluwaseun O Falade-Nwulia²

124.

Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada

Int J Drug Policy. 2020 Jun;80:102755. doi: 10.1016/j.drugpo.2020.102755. Epub 2020 May 14.

Jennifer Broad¹, Kate Mason¹, Mary Guyton², Bernadette Lettner³, John Matelski⁴, Jeff Powis⁵

125.

English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed

Kathryn Drysdale^1 2, Yevedzo Ntuli^1 3, Jonathan Bestwick⁴, William Gelson⁵, Kosh Agarwal³, Daniel Forton⁶, David Mutimer⁷, Ahmed M Elsharkawy⁷, Ceri Townley⁸, Faizel Mahomed⁹, Graham R Foster^1 2

Aliment Pharmacol Ther. 2020 Jul;52(1):168-181. doi: 10.1111/apt.15780. Epub 2020 May 22.

126.

Ethical and Practical Issues Associated with the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine

Clin Infect Dis. 2020 May 22;ciaa640. doi: 10.1093/cid/ciaa640. Online ahead of print.

Andrea Cox^1 2, Mark Sulkowski¹, Jeremy Sugarman^1 2 3

Affiliations collapse

127.

Impact of the Centers for Disease Control and Prevention Recommendation and State Law on Birth Cohort Hepatitis C Screening of New York City Medicaid Recipients

Am J Prev Med. 2020 Jun;58(6):832-838. doi: 10.1016/j.amepre.2019.12.024.

Angelica Bocour¹, Miranda S Moore², Ann Winters²

128.

"Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs

Int J Drug Policy. 2020 Jul;81:102766. doi: 10.1016/j.drugpo.2020.102766. Epub 2020 May 13.

Trevor Goodyear¹, Lianping Ti², Patrizia Carrieri³, Will Small⁴, Rod Knight⁵

129.

Resistance-associated Substitutions in Patients With Chronic Hepatitis C Virus Genotype 4 Infection

J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.

Julia Dietz^1 2, Olga V Kalinina^3 4, Johannes Vermehren^1 2, Kai-Henrik Peiffer^1 2, Katrin Matschenz⁵, Peter Buggisch⁵, Claus Niederau⁶, Jörn M Schattenberg⁷, Beat Müllhaupt⁸, Sabine Yerly⁹, Marc Ringelhan¹⁰, Roland M Schmid¹⁰, Christoph Antoni¹¹, Tobias Müller¹², Julian Schulze Zur Wiesch^13 14, Felix Piecha¹³, Darius Moradpour¹⁵, Katja Deterding^16 17 18, Heiner Wedemeyer^16 17 18, Christophe Moreno¹⁹, Thomas Berg²⁰, Christoph P Berg²¹, Stefan Zeuzem^1 2, Christoph Welsch^1 2, Christoph Sarrazin^1 2 22, European HCV Resistance Study Group

130.

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment

Ann Pharmacother. 2020 May 14;1060028020921166. doi: 10.1177/1060028020921166.Online ahead of print.

Ashley H McKnight¹, Mary L Townsend¹, Mohamed G Hashem¹, Susanna Naggie^1 2 3, Lawrence P Park^1 2 4, Rachel B Britt¹

131.

HCV DAA Therapy in Persons With HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation

J Infect Dis. 2020 May 15;jiaa254.doi: 10.1093/infdis/jiaa254. Online ahead of print.

Donald D Anthony¹, Mark S Sulkowski², Laura M Smeaton³, Sofi Damjanovska¹, Carey L Shive¹, Corinne M Kowal¹, Daniel E Cohen⁴, Debika Bhattacharya⁵, Beverly L Alston-Smith⁶, Ashwin Balagopal², David L Wyles⁷

132.

High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017

MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574 doi: 10.15585/mmwr.mm6919a1.

James W Galbraith, Erik S Anderson, Yu-Hsiang Hsieh, Ricardo A Franco, John P Donnelly, Joel B Rodgers, Elissa M Schechter-Perkins, William W Thompson, Noele P Nelson, Richard E Rothman, Douglas A E White

Free PMC article

133.

Impact of Treatment With Direct Acting Antiviral Drugs on Glycemic Control in Patients With Hepatitis C and Diabetes Mellitus

Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155/2020/6438753. eCollection 2020.

Pradeep Kumar Mada^1 2, Matthew E Malus³, Arvin Parvathaneni⁴, Bing Chen³, Gabriel Castano⁵, Sharon Adley², Maureen Moore², Michinari Hieda⁶, Mohammed J Alam², Mark Feldman¹, John William King²

134.

Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation

Gastroenterol Clin North Am. 2020 Jun;49(2):253-277.doi: 10.1016/j.gtc.2020.01.005. Epub 2020 Mar 29.

Marianne Martinello¹, Sahar Bajis², Gregory J Dore²

135.

Hepatitis C: How Good Are Real-Life Data and Do Generics Work

Gastroenterol Clin North Am. 2020 Jun;49(2):279-299.doi: 10.1016/j.gtc.2020.01.006. Epub 2020 Mar 29.

Ashley N Tran¹, Joseph K Lim²

136.

Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?

Gastroenterol Clin North Am. 2020 Jun;49(2):301-314.doi: 10.1016/j.gtc.2020.01.007. Epub 2020 Mar 29.

Humberto C Gonzalez¹, Stuart C Gordon²

137.

Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010-2016: Gaps to Elimination

Popul Health Manag. 2020 May 11. doi: 10.1089/pop.2019.0237. Online ahead of print.

Josephine Nhu Tran¹, Robert J Wong², Janet S Lee³, Tim Bancroft¹, Ami R Buikema¹, Jie Ting³, Norah Terrault⁴

138.

Global Epidemiology of Viral Hepatitis

Gastroenterol Clin North Am. 2020 Jun;49(2):179-189.doi: 10.1016/j.gtc.2020.01.001.

Homie Razavi¹

139.

Eliciting Patient Views on the Allocation of Limited Healthcare Resources: A Deliberation on Hepatitis C Treatment in the Veterans Health Administration

BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.

Akbar K Waljee^1 2 3, Kerry A Ryan⁴, Chris D Krenz⁴, George N Ioannou^5 6, Lauren A Beste^6 7, Monica A Tincopa⁸, Sameer D Saini^9 8 10, Grace L Su^9 8, Maria E Arasim⁹, Patti T Roman⁹, Brahmajee K Nallamothu^9 10 11, Raymond De Vries⁴

140.

Bayesian Network Modelling Study to Identify Factors Influencing the Risk of Cardiovascular Disease in Canadian Adults With Hepatitis C Virus Infection

MJ Open. 2020 May 5;10(5):e035867. doi: 10.1136/bmjopen-2019-035867.

Alaa Badawi^1 2, Giancarlo Di Giuseppe^3 4, Alind Gupta⁵, Abbey Poirier⁶, Paul Arora³

141.

Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model

Open. 2020 May 1;3(5):e204192. doi: 10.1001/jamanetworkopen.2020.4192.

Mawuena Binka¹, Naveed Z Janjua^1 2 3, Jason Grebely^2 4, Chris Estes⁵, Dena Schanzer², Jisoo A Kwon⁴, Naglaa H Shoukry^2 6, Jeffrey C Kwong^2 7, Homie Razavi⁵, Jordan J Feld^2 8, Mel Krajden^1 2 3

142.

Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients With Hepatitis C and Hepatocellular Carcinoma

Vasc Interv Radiol. 2020 Jun;31(6):953-960. doi: 10.1016/j.jvir.2019.12.809. Epub 2020 May 4.

William M Kamp¹, Cortlandt M Sellers¹, Stacey Stein², Joseph K Lim³, Hyun S Kim⁴

143.

Impact of a Digital Medicine Programme on Hepatitis C Treatment Adherence and Efficacy in Adults at High Risk for Non-Adherence

Aliment Pharmacol Ther. 2020 Jun;51(12):1384-1396. doi: 10.1111/apt.15707. Epub 2020 Apr 30.

Mark Sulkowski¹, Annie F Luetkemeyer², David L Wyles³, Claudia Martorell⁴, Andrew Muir⁵, Ilan Weisberg⁶, Stuart C Gordon⁷, Richard McLain⁸, Gregory Huhn^3 8

144.

Japan Society of Hepatology Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update

Hepatol Res. 2020 Apr 28. doi: 10.1111/hepr.13503. Online ahead of print.

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology

145.

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection

Biology (Basel). 2020 Apr 24;9(4):87. doi: 10.3390/biology9040087.

Leigh P Johnson¹, Richard K Sterling^1 2 3

146.

Utilization and Effectiveness of elbasvir/grazoprevir and Adoption of Resistance-Associated Substitutions Testing in Real-World Treatment of Hepatitis C Virus Genotype 1A Infection: Results From the German Hepatitis C-Registry

Eur J Gastroenterol Hepatol. 2020 May 15. doi: 10.1097/MEG.0000000000001759.Online ahead of print.

Holger Hinrichsen¹, Albrecht Stoehr², Markus Cornberg³, Hartwig Klinker⁴, Renate Heyne⁵, Christine John⁶, Karl-Georg Simon⁷, Veronika Guenther⁸, Karen Martin⁸, Vanessa Witte⁸, Stefan Zeuzem⁹

147.

Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. doi: 10.2147/JHC.S221187.eCollection 2020.

Srikanta Dash^1 2 3, Yucel Aydin¹, Kyle E Widmer², Leela Nayak²

148.

Antibody Responses in Hepatitis C Infection

Cold Spring Harb Perspect Med. 2020 Apr 27;a036962.doi: 10.1101/cshperspect.a036962.Online ahead of print.

Mansun Law¹

149.

Hepatitis C Prevalence and Risk Factors in Georgia, 2015: Setting a Baseline for Elimination

BMC Public Health. 2019 May 10;19(Suppl 3):480. doi: 10.1186/s12889-019-6784-3.

Liesl M Hagan¹, Ana Kasradze², Stephanie J Salyer³, Amiran Gamkrelidze², Maia Alkhazashvili², Gvantsa Chanturia², Nazibrola Chitadze², Roena Sukhiashvili², Marina Shakhnazarova², Steven Russell³, Curtis Blanton³, Giorgi Kuchukhidze², Davit Baliashvili², Susan Hariri⁴, Stephen Ko^4 5, Paata Imnadze², Jan Drobeniuc⁴, Juliette Morgan^3 6, Francisco Averhoff⁴

150.

An Evaluation of the Hepatitis C Testing, Care and Treatment Program in the Country of Georgia's Corrections System, December 2013 - April 2015

BMC Public Health. 2019 May 10;19(Suppl 3):466. doi: 10.1186/s12889-019-6783-4.

Aaron M Harris¹, Otar Chokoshvili², Joshua Biddle³, Kostantine Turashvili⁴, Maia Japaridze⁵, Irma Burjanadze⁶, Tengiz Tsertsvadze², Lali Sharvadze², Marine Karchava², Archil Talakvadze⁷, Ketevan Chakhnashvili⁴, Tamta Demurishvili⁴, Paata Sabelashvili⁸, Monique Foster^9 10, Liesl Hagan⁹, Maia Butsashvili¹¹, Juliette Morgan^5 12, Francisco Averhoff⁹

151.

HCV Knowledge, Disclosure Practices, and Risk Perceptions Among Gay and Bisexual Men Who Do and Do Not Engage in Group Sex While Using Drugs

AIDS Care. 2020 Apr 26;1-4. doi: 10.1080/09540121.2020.1757023. Online ahead of print.

Loren Brener¹, Dean A Murphy², Elena Cama¹, Joel Murray³, Neil Fraser⁴, Jeanne Ellard⁵

152.

Excess Weight Gain After Cure of Hepatitis C Infection With Direct-Acting Antivirals

J Gen Intern Med. 2020 Apr 27. doi: 10.1007/s11606-020-05782-6. Online ahead of print.

Albert Do¹, Denise A Esserman², Supriya Krishnan^3 4, Joseph K Lim^5 4, Tamar H Taddei^5 4, Ronald G Hauser 3rd^4 6, Janet P Tate^3 4, Vincent Lo Re 3rd^7 8, Amy C Justice^3 4

153.

Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review

J Clin Gastroenterol. 2020 Apr 21. doi: 10.1097/MCG.0000000000001360. Online ahead of print.

Sammy Saab^1 2 3, Ravina Kullar⁴, Haydar Khalil¹, Prabhu Gounder⁵

154.

Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

Clin Infect Dis. 2020 Apr 13;ciaa362.doi: 10.1093/cid/ciaa362. Online ahead of print.

Antoine Chaillon¹, Adriane Wynn², Tatyana Kushner³, Nancy Reau⁴, Natasha K Martin^1 5

155.

HCC Recurrence in HCV-infected Patients After Liver Transplantation: SiLVER Study Reveals Benefits of Sirolimus in Combination With CNIs - A Post-Hoc Analysis

Transpl Int. 2020 Apr 21. doi: 10.1111/tri.13621. Online ahead of print.

Jens M Werner¹, Matthias Hornung¹, Rubertha Krah¹, Markus Götz¹, Andreas A Schnitzbauer^1 2, Hans J Schlitt¹, Edward K Geissler^1 3, International SiLVER study group

156.

Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People Who Inject Drugs in San Francisco, California

Forum Infect Dis. 2020 Mar 16;7(4):ofaa092. doi: 10.1093/ofid/ofaa092.eCollection 2020 Apr.

Yuridia Leyva¹, Kimberly Page², Stephen Shiboski³, Judith A Hahn⁴, Jennifer Evans³, Erik Erhardt⁵

157.

Hepatitis C Virus in Pregnancy: A Systematic Review of the Literature

Am J Perinatol. 2020 Apr 22. doi: 10.1055/s-0040-1709672. Online ahead of print.

Alexandra Andes¹, Kerry Ellenberg¹, Amanda Vakos¹, James Collins¹, Kimberly Fryer²

158.

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation

Kidney Int Rep. 2020 Jan 13;5(4):459-467.doi: 10.1016/j.ekir.2020.01.001. eCollection 2020 Apr.

Meghan E Sise¹, Ian A Strohbehn², Donald F Chute², Jenna Gustafson², Vivianna M Van Deerlin³, Jennifer R Smith³, Caren Gentile³, David Wojciechowski⁴, Winfred W Williams¹, Nahel Elias⁵, Raymond T Chung²

159.

CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie¹, Carolyn Wester¹, Melissa Osborne¹, Laura Wesolowski¹, A Blythe Ryerson¹

160.

Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection

J Clin Transl Hepatol. 2020 Mar 28;8(1):25-41. doi: 10.14218/JCTH.2019.00059.Epub 2020 Mar 24.

Cynthia J Tsay¹, Joseph K Lim²

161.

Maternal Hepatitis B or Hepatitis C Virus Carrier Status and Long-Term Infectious Morbidity of the Offspring: A Population-Based Cohort Study

J Viral Hepat. 2020 Apr 9.doi: 10.1111/jvh.13300. Online ahead of print.

Naim Abu Freha¹, Tamar Wainstock², Liat Poupko³, Avni Yonat Shemer⁴, Ruslan Sergienko², Eyal Sheiner⁵

162.

Viral Eradication Restores Normal Iron Status in Chronic Hepatitis C Patients With Abnormal Iron Studies

Ann Hepatol. 2020 Mar 17;S1665-2681(20)30024-7.doi: 10.1016/j.aohep.2020.03.002.Online ahead of print.

Yazan Hasan¹, Kyle Brown²

163.

Outcomes of Liver Transplantation by Insurance Types in the United States

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi¹

164.

Outcomes of Liver Transplantation by Insurance Types in the United States

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi¹

165.

KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C

Am J Kidney Dis. 2020 May;75(5):665-683. doi: 10.1053/j.ajkd.2019.12.016. Epub 2020 Apr 9.

David Roth¹, Roy D Bloom², Miklos Z Molnar³, Peter P Reese⁴, Deirdre Sawinski⁵, Meghan E Sise⁶, Norah A Terrault⁷

166.

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients With Chronic Hepatitis C Infection

Adv Ther. 2020 May;37(5):2267-2274. doi: 10.1007/s12325-020-01301-5. Epub 2020 Apr 11.

Steven L Flamm¹, Jens Kort², Steven E Marx³, John Strezewski², Douglas E Dylla², Bruce Bacon⁴, Michael P Curry⁵, Naoky Tsai⁶, Nicole Wick⁷

167.

CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie¹, Carolyn Wester¹, Melissa Osborne¹, Laura Wesolowski¹, A Blythe Ryerson¹

168.

Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018

MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404.doi: 10.15585/mmwr.mm6914a2.

A Blythe Ryerson¹, Sarah Schillie¹, Laurie K Barker¹, Benjamin A Kupronis¹, Carolyn Wester¹

169.	Factors Influencing Treatment Outcome in Hepatitis C Virus Minority Patients at an Inner-City Hospital: A STROBE-complaint Article
	Zaki A Sherif¹, Mehdi Nouraie², Rehana Begum^2 3, Ali Afsari^4 5, Babak Shokrani⁵, Edward Lee^5 6, Adeyinka O Laiyemo^2 3, Hassan Brim^4 6, Hassan Ashktorab^2 4

170.

Simeprevir, Daclatasvir, and Sofosbuvir for Hepatitis C Virus-Infected Patients: Long-term Follow-Up Results From the Open-Label, Phase II IMPACT Study

Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.

Eric Lawitz¹, Fred Poordad¹, Julio A Gutierrez², Maria Beumont³, Greet Beets³, Ann Vandevoorde³, Pieter Van Remoortere⁴, Donghan Luo⁴, Leen Vijgen³, Veerle Van Eygen³, Mohamed Gamil³

171.

Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People With Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial

Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun.

Jason Grebely¹, Phillip Read², Evan B Cunningham¹, Martin Weltman³, Gail V Matthews^1 4, Adrian Dunlop⁵, Mark Montebello⁶, Marianne Martinello^1 4, Rosie Gilliver², Philippa Marks¹, Tanya L Applegate¹, Gregory J Dore^1 4, DARLO-C Study Group

172.

Infective Endocarditis Among Persons Aged 18-64 Years With HIV, Hepatitis C Infection, or Opioid Use Disorder - United States, 2007-2017

Clin Infect Dis. 2020 Apr 9;ciaa372. doi: 10.1093/cid/ciaa372. Online ahead of print.

Cecillia Y Wong¹, Weiming Zhu², Gerard P Aurigemma¹, Nathan Furukawa², Eyasu H Teshale³, Ya-Lin A Huang², Philip J Peters², Karen W Hoover²

173.

The Emergency Department as a Setting-Specific Opportunity for Population-Based Hepatitis C Screening: An Economic Evaluation

Liv Int. 2020 Apr 8. doi: 10.1111/liv.14458. Online ahead of print.

Andrew B Mendlowitz^1 2, David Naimark³, William W L Wong⁴, Camelia Capraru⁵, Jordan J Feld⁵, Wanrudee Isaranuwatchai^2 6, Murray Krahn^1 7

174.

Ombitasvir/paritaprevir/ritonavir & Dasabuvir ± Ribavirin Following Protease Inhibitors Failure - A Prospective Multi-Centre Trial

BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.

Liat Deutsch^1 2, Inbal Houri^1 2, Ziv Ben-Ari^2 3, Amir Shlomai^2 4, Ella Veitsman^2 3, Oranit Cohen-Ezra^2 3, Assaf Issachar^2 4, Orna Mor^5 6, Yael Gozlan⁵, Rafael Bruck^1 2, Yoram Menachem^1 2, Shira Zelber-Sagi^1 7, Helena Katchman^1 2, Oren Shibolet^8 9

175.

How to Think With Models and Targets: Hepatitis C Elimination as a Numbering Performance

Int J Drug Policy. 2020 Mar 31;102694. doi: 10.1016/j.drugpo.2020.102694. Online ahead of print.

Tim Rhodes¹, Kari Lancaster²

176.

Is Alzheimer's Disease a Liver Disease of the Brain?

Alzheimers Dis. 2020 Apr 2.doi: 10.3233/JAD-190848. Online ahead of print.

Margaret F Bassendine^1 2, Simon D Taylor-Robinson², Michael Fertleman^2 3, Michael Khan⁴, Dermot Neely^1 5

177.

Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017

J Clin Gastroenterol. 2020 Apr 3. doi: 10.1097/MCG.0000000000001344. Online ahead of print.

Philip R Spradling¹, Jian Xing¹, Loralee B Rupp², Anne C Moorman¹, Stuart C Gordon^2 3, Mei Lu², Eyasu H Teshale¹, Joseph A Boscarino⁴, Mark A Schmidt⁵, Yihe G Daida⁶, Scott D Holmberg¹, Chronic Hepatitis Cohort Study (CHeCS) Investigators

178.

Use of Electronic Health Records at Federally Qualified Health Centers: A Potent Tool to Increase Viral Hepatitis Screening and Address the Climbing Incidence of Liver Cancer

Cancer Educ. 2020 Apr 2. doi: 10.1007/s13187-020-01741-1. Online ahead of print.

Christina Pham¹, Mo-Kyung Sin²

179.

Antibody Avidity-Based Approach to Estimate Population-Level Incidence of Hepatitis C

Hepatol. 2020 Mar 30;S0168-8278(20)30190-2. doi: 10.1016/j.jhep.2020.03.028.Online ahead of print.

Denali Boon¹, Veronica Bruce², Eshan U Patel³, Jeffery Quinn³, Aylur K Srikrishnan⁴, Saravanan Shanmugam⁴, Syed Iqbal⁴, Pachamuthu Balakrishnan⁴, Matthew Sievers³, Gregory D Kirk³, David L Thomas³, Thomas C Quinn⁵, Andrea L Cox³, Kimberly A Page², Sunil S Solomon⁶, Shruti H Mehta³, Oliver Laeyendecker⁵

180.

Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans

J Cardiovasc Drugs. 2020 Apr 1. doi: 10.1007/s40256-020-00404-2. Online ahead of print.

S S Sutton^1 2, Joseph Magagnoli^3 4, Tammy H Cummings², James W Hardin^2 5

181.

Health of Special Immigrant Visa Holders From Iraq and Afghanistan After Arrival Into the United States Using Domestic Medical Examination Data, 2014-2016: A Cross-Sectional Analysis

PLoS Med. 2020 Mar 31;17(3):e1003083. doi: 10.1371/journal.pmed.1003083.eCollection 2020 Mar.

Gayathri S Kumar¹, Clelia Pezzi¹, Simone Wien¹, Blain Mamo², Kevin Scott³, Colleen Payton³, Kailey Urban², Stephen Hughes⁴, Lori Kennedy⁵, Nuny Cabanting⁶, Jessica Montour⁷, Melissa Titus⁸, Jenny Aguirre⁹, Breanna Kawasaki⁵, Rebecca Ford¹⁰, Emily S Jentes¹

182.

Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis

Intern Me. 2020;59(7):901-907. doi: 10.2169/internalmedicine.3382-19. Epub 2020 Apr 1.

Satoshi Miuma¹, Junya Miyamoto², Naota Taura¹, Masanori Fukushima¹, Ryu Sasaki¹, Masafumi Haraguchi¹, Hidetaka Shibata¹, Shuntaro Sato², Hisamitsu Miyaaki¹, Kazuhiko Nakao¹

183.

Prescription Opioid Injection Among Young People Who Inject Drugs in New York City: A Mixed-Methods Description and Associations With Hepatitis C Virus Infection and Overdose

Harm Reduct J. 2020 Mar 30;17(1):22. doi: 10.1186/s12954-020-00367-2.

Pedro Mateu-Gelabert¹, Honoria Guarino², Jon E Zibbell³, Jennifer Teubl⁴, Chunki Fong², Elizabeth Goodbody², Brian Edlin⁵, Carli Salvati², Samuel R Friedman⁶

184.

Measuring Hepatitis C Virus Elimination as a Public Health Threat: Beyond Global Targets

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294. Online ahead of print.

Daniela K van Santen^1 2 3, Rachel Sacks-Davis^1 3, Joseph S Doyle^1 4, Nick Scott^1 3, Maria Prins^2 5, Margaret Hellard^1 4 6

185.

The Impact of SVR From Direct-Acting Antiviral- And Interferon-Based Treatments for HCV on Hepatocellular Carcinoma Risk

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295. Online ahead of print.

Naveed Z Janjua^1 2, Stanley Wong¹, Maryam Darvishian^1 2 3, Zahid A Butt^1 2, Amanda Yu¹, Mawuena Binka¹, Maria Alvarez¹, Ryan Woods³, Eric M Yoshida⁴, Alnoor Ramji⁴, Jordan Feld⁵, Mel Krajden^1 6

186.

Hepatitis C: Looking Into the Future

Expert Rev Gastroenterol Hepatol. 2020 Mar 27;1-8.

doi: 10.1080/17474124.2020.1746641.Online ahead of print.

Omar Massoud¹

187.

Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN)

J Pediatr Gastroenterol Nutr. 2020 Mar 20.

doi: 10.1097/MPG.0000000000002710.Online ahead of print.

Giuseppe Indolfi¹, Björn Fischler², Regino P Gonzalez-Peralta³, Mirta Ciocca⁴, Gilda Porta⁵, Mohan Neelam⁶, Mohammed El-Guindi⁷, Deirdre Kelly⁸, Yen-Hsuan Ni⁹, Anupan Sibal¹⁰, Daniel H Leung¹¹, Mei Hwei Chang¹², Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)

188.

Population Impact of Direct-Acting Antiviral Treatment on New Presentations of Hepatitis C-related Decompensated Cirrhosis: A National Record-Linkage Study

Gut. 2020 Mar 26;gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007. Online ahead of print.

Sharon J Hutchinson^1 2, Heather Valerio^3 2, Scott A McDonald^3 2, Alan Yeung^3 2, Kevin Pollock^3 2, Shanley Smith^3 2, Stephen Barclay^3 4, John F Dillon⁵, Raymond Fox⁶, Peter Bramley⁷, Andrew Fraser^8 9, Nicholas Kennedy¹⁰, Rory N Gunson¹¹, Kate Templeton¹², Hamish Innes^3 2, Allan McLeod², Amanda Weir², Peter C Hayes¹³, David Goldberg^3 2

189.	New hepatitis C diagnoses in Ontario, Canada are associated with the local prescription patterns of a controlled-release opioid
	Meyer M^1,2,3, Bondy L⁴, Koivu S⁵, Koval J², Scarffe AD^3,6, Silverman MS⁴. J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292. [Epub ahead of print]

190.	Hepatitis C: looking into the future
	Massoud O¹. Expert Rev Gastroenterol Hepatol. 2020 Mar 27:1-8. doi: 10.1080/17474124.2020.1746641. [Epub ahead of print]

191.	Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
	Wong RJ¹, Jain MK^2,3, Therapondos G⁴, Shiffman ML⁵, Kshirsagar O⁶, Clark C³, Thamer M⁶. J Clin Exp Hepatol. 2020 Mar-Apr;10(2):114-123. doi: 10.1016/j.jceh.2019.09.001. Epub 2019 Sep 20.

192.	T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy
	Smith S^1,2, Honegger JR^1,2, Walker C^1,2. Cold Spring Harb Perspect Med. 2020 Mar 23. pii: a036954. doi: 10.1101/cshperspect.a036954. [Epub ahead of print]

193.	Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
	Banga J¹, Nizami S¹, Slim J², Nagarakanti S³, Portilla M¹, Swaminathan S¹. Medicine (Baltimore). 2020 Mar;99(11):e19140. doi: 10.1097/MD.0000000000019140.

194.	Australia needs to increase testing to achieve hepatitis C elimination
	Scott N¹, Sacks-Davis R¹, Wade AJ¹, Stoove M¹, Pedrana A¹, Doyle JS¹, Thompson AJ², Wilson DP¹, Hellard ME¹. Med J Aust. 2020 Mar 13. doi: 10.5694/mja2.50544. [Epub ahead of print]

195.	The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action
	Saab S¹, Kullar R, Gounder P. Obstet Gynecol. 2020 Apr;135(4):773-777. doi: 10.1097/AOG.0000000000003704.

196.	Present and future management of viral hepatitis B and C in children
	Clemente MG¹, Antonucci R², Sotgiu G², Dettori M², Piana A², Vajro P³. Clin Res Hepatol Gastroenterol. 2020 Mar 12. pii: S2210-7401(20)30043-7. doi: 10.1016/j.clinre.2020.02.010. [Epub ahead of print]

197.

Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors

Prasad M¹, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Obstet Gynecol. 2020 Apr;135(4):778-788. doi: 10.1097/AOG.0000000000003754.

198.

Reinfection following successful direct-acting antiviral therapy for hepatitis Cinfection among people who inject drugs

Cunningham EB¹, Hajarizadeh B¹, Amin J^1,2, Hellard M^3,4, Bruneau J⁵, Feld JJ⁶, Cooper C⁷, Powis J⁸, Litwin AH⁹, Marks P¹, Dalgard O¹⁰, Conway B¹¹, Moriggia A^12,13, Stedman C¹⁴, Read P^1,15, Bruggmann P¹⁶, Lacombe K¹⁷, Dunlop A¹⁸, Applegate TL¹, Matthews GV^1,19, Fraser C²⁰, Dore GJ^1,19, Grebely J¹. Clin Infect Dis. 2020 Mar 12. pii: ciaa253. doi: 10.1093/cid/ciaa253. [Epub ahead of print]

199.	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
	Stone J¹, Fraser H², Young AM³, Havens JR⁴, Vickerman P². Int J Drug Policy. 2020 Mar 6:102707. doi: 10.1016/j.drugpo.2020.102707. [Epub ahead of print]

200.	A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy
	Akiyama MJ¹, Lipsey D¹, Ganova-Raeva L², Punkova L², Agyemang L¹, Sue A², Ramachandran S², Khudyakov Y², Litwin AH³. J Infect Dis. 2020 Mar 9. pii: jiaa100. doi: 10.1093/infdis/jiaa100. [Epub ahead of print]

201.	Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C
	Henson JB¹, Wilder JM^2,3, Kappus MR², Barbas AS⁴, Moylan CA², Niedzwiecki D⁵, Muir AJ^2,3, Berg CL², Patel YA². Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219. [Epub ahead of print]

202.	Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016
	Bradley H¹, Hall EW², Rosenthal EM³, Sullivan PS², Ryerson AB⁴, Rosenberg ES³. Hepatol Commun. 2020 Jan 14;4(3):355-370. doi: 10.1002/hep4.1457. eCollection 2020 Mar.

203.	Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States
	Grov C^1,2, Westmoreland DA², Carrico AW^3,4, Nash D^1,2. AIDS Care. 2020 Mar 15:1-9. doi: 10.1080/09540121.2020.1739204. [Epub ahead of print]

204.	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry
	Knop V¹, Mauss S², Goeser T³, Geier A⁴, Zimmermann T⁵, Herzer K⁶, Postel N⁷, Friedrich-Rust M¹, Hofmann WP⁸; German Hepatitis C-Registry⁹. J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280. [Epub ahead of print]

205.	A vulnerability assessment for the HCV infections associated with injection drug use
	Sharareh N¹, Hess R², White S³, Dunn A⁴, Singer PM⁵, Cochran J⁶. Prev Med. 2020 Feb 22;134:106040. doi: 10.1016/j.ypmed.2020.106040. [Epub ahead of print]

206.	Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C
	Moitra E¹, Anderson BJ², Herman DS^1,2, Hayaki J³, Pinkston MM^1,4, Kim HN^5,6, Stein MD⁷. AIDS Care. 2020 Feb 25:1-8. doi: 10.1080/09540121.2020.1734177. [Epub ahead of print]

207.	Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care
	Roberts K¹, Macleod J^1,2, Metcalfe C^1,3, Hollingworth W¹, Williams J^4,5, Muir P⁶, Vickerman P^1,2, Clement C², Gordon F⁷, Irving W⁸, Waldron CA⁹, North P⁶, Moore P⁶, Simmons R^5,10, Miners A^4,5, Horwood J^1,2, Hickman M^11,2. BMJ. 2020 Feb 26;368:m322. doi: 10.1136/bmj.m322.

208.	Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial
	Horwood J¹, Clement C², Roberts K², Waldron CA³, Irving WL⁴, Macleod J⁵, Hickman M⁶. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]Horwood J¹, Clement C², Roberts K², Waldron CA³, Irving WL⁴, Macleod J⁵, Hickman M⁶. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]

209.	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
	Colledge S¹, Leung J², Grebely J³, Degenhardt L⁴, Peacock A⁴, Hickman M⁵, Vickerman P⁵, Stone J⁵, Trickey A⁵, Larney S⁴. Drug Alcohol Depend. 2020 Feb 6;209:107899. doi: 10.1016/j.drugalcdep.2020.107899. [Epub ahead of print]

210.	Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis CTreatment: A Randomized Controlled Trial
	Davis JS^1,2, Young M¹, Marshall C³, Tate-Baker J³, Madison M³, Sharma S³, Silva C¹, Jones T¹, Davies J^2,3. Open Forum Infect Dis. 2020 Jan 19;7(2):ofaa022. doi: 10.1093/ofid/ofaa022. eCollection 2020 Feb.

211.	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients
	Eckman MH¹, Woodle ES², Thakar CV³, Alloway RR³, Sherman KE⁴. Am J Kidney Dis. 2020 Feb 5. pii: S0272-6386(19)31163-1. doi: 10.1053/j.ajkd.2019.11.005. [Epub ahead of print]

212.	The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida
	Pinheiro PS¹, Medina HN², Callahan KE³, Jones PD⁴, Brown CP⁵, Altekruse SF⁶, McGlynn KA⁷, Kobetz EN⁸. Liver Int. 2020 Feb 22. doi: 10.1111/liv.14409. [Epub ahead of print]

213.	Diagnostic Accuracy of Non-Invasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease
	Schmoyer CJ¹, Kumar D², Gupta G², Sterling RK³. Clin Gastroenterol Hepatol. 2020 Feb 18. pii: S1542-3565(20)30189-0. doi: 10.1016/j.cgh.2020.02.019. [Epub ahead of print]

214.	Hepatitis C Virus Vaccine: Challenges and Prospects
	Duncan JD^1,2,3, Urbanowicz RA^1,2,3, Tarr AW^1,2,3, Ball JK^1,2,3. Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090.

215.	Micro-elimination of hepatitis C virus
	Hollande C¹, Parlati L¹, Pol S¹. Liver Int. 2020 Feb;40 Suppl 1:67-71. doi: 10.1111/liv.14363

216.	Hepatitis C elimination - Macro-elimination
	Kåberg M^1,2, Weiland O¹. Liver Int. 2020 Feb;40 Suppl 1:61-66. doi: 10.1111/liv.14352.

217.	Increased-risk donors and solid organ transplantation: current practices and opportunities for improvement
	Brown CS¹, Wakam GK, Englesbe MJ. Curr Opin Organ Transplant. 2020 Apr;25(2):139-143. doi: 10.1097/MOT.0000000000000735

218.	Case Management and Capacity Building to Enhance Hepatitis C Treatment Uptake at Community Health Centers in a Large Urban Setting
	Boodram B¹, Kaufmann M, Aronsohn A, Hamlish T, Peregrine Antalis E, Kim K, Wolf J, Rodriguez I, Millman AJ, Johnson D. Fam Community Health. 2020 Apr/Jun;43(2):150-160. doi: 10.1097/FCH.0000000000000253

219.	HCV infection and non-Hodgkin lymphomas: an evolving story
	Defrancesco I¹, Zerbi C¹, Rattotti S², Merli M³, Bruno R^4,5, Paulli M^1,6, Arcaini L^7,8. Clin Exp Med. 2020 Feb 12. doi: 10.1007/s10238-020-00615-6. [Epub ahead of print]

220.	Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy
	Gross MS¹, Ruth AR², Rasmussen SA^3,4. J Med Ethics. 2020 Feb 13. pii: medethics-2019-105692. doi: 10.1136/medethics-2019-105692. [Epub ahead of print]

221.	Discontinuation of new hepatitis C drugs among Medicare patients
	Jung J¹, Du P, Feldman R, Riley T 3rd. Am J Manag Care. 2020 Feb;26(2):84-88. doi: 10.37765/ajmc.2020.42397

222.	Hepatitis C Testing Among Perinatally Exposed Infants
	Lopata SM^1,2, McNeer E^3,4, Dudley JA⁵, Wester C⁶, Cooper WO^7,3,5, Carlucci JG^7,8, Espinosa CM^9,10, Dupont W^4,5, Patrick SW^7,2,3,5. Pediatrics. 2020 Mar;145(3). pii: e20192482. doi: 10.1542/peds.2019-2482. Epub 2020 Feb 14.

223.	Hepatitis C vaccine: 10 good reasons for continuing
	Roingeard P¹, Beaumont E¹. Hepatology. 2020 Feb 15. doi: 10.1002/hep.31182. [Epub ahead of print]

224.	Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)
	Schmitt A¹, Günther R², Mauss S³, Boeker KHW⁴, Buggisch P⁵, Hillenbrand H⁶, John C⁷, Klinker H⁸, Pathil A^9,10, Simon KG¹¹, Serfert Y¹², Niederau C¹³, Vermehren J¹⁰, Wedemeyer H^12,14,15, Sarrazin C^1,10. Z Gastroenterol. 2020 Feb 10. doi: 10.1055/a-1068-3056. [Epub ahead of print]

225.	The Next Frontier: Universal HCV Screening in pregnant women
	Saab S¹, Kullar R², Amini C³, Gounder P⁴. Am J Obstet Gynecol. 2020 Feb 7. pii: S0002-9378(20)30133-2. doi: 10.1016/j.ajog.2020.01.058. [Epub ahead of print]

226.	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care
	Falade-Nwulia O¹, Ward KM¹, McCormick S¹, Mehta SH², Pitts SR³, Katz S¹, Chander G¹, Thomas DL¹, Sulkowski M¹, Latkin CA². J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274. [Epub ahead of print]

227.	A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program
	Lee KS^1,2, Quintiliani L^1,3, Heinz A⁴, Johnson NL³, Xuan Z³, Truong V², Lasser KE^1,2,3. PLoS One. 2020 Feb 11;15(2):e0228767. doi: 10.1371/journal.pone.0228767. eCollection 2020

228.	Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment
	Kim NJ¹, Pearson M¹, Vutien P¹, Su F¹, Moon AM², Berry K³, Green PK³, Williams EC^3,4, Ioannou GN^1,5. Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. eCollection 2020 Feb.

229.	HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017
	Bull-Otterson L¹, Huang YA², Zhu W³, King H⁴, Edlin BR¹, Hoover KW². J Infect Dis. 2020 Jan 30. pii: jiaa017. doi: 10.1093/infdis/jiaa017. [Epub ahead of print]

230.	Exploring Awareness of HCV Among Sexual-Minority Black Generation Millennials and Gen Z: a Qualitative Study
	D'Anna L¹, Washington TA², Cabudol M³, Canjura C³, Owens J³; PPOWER Project Team. J Racial Ethn Health Disparities. 2020 Jan 31. doi: 10.1007/s40615-019-00684-8. [Epub ahead of print]

231.	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation
	Jordan AE¹, Perlman DC², Cleland CM³, Wyka K⁴, Schackman BR⁵, Nash D⁴. J Clin Virol. 2020 Jan 27;124:104285. doi: 10.1016/j.jcv.2020.104285. [Epub ahead of print]

232.	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study
	Adinolfi LE¹, Petta S², Fracanzani AL³, Coppola C⁴, Narciso V⁵, Nevola R⁶, Rinaldi L⁶, Calvaruso V², Staiano L⁴, Di Marco V², Marrone A⁶, Pafundi PC⁶, Solano A⁵, Lombardi R³, Sasso FC⁶, Saturnino M⁴, Rini F², Guerrera B⁶, Troina G², Giordano M⁶, Craxì A². Atherosclerosis. 2020 Jan 21;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. [Epub ahead of print]

233.	Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs
	Rosenthal ES^1,2, Silk R^1,2, Mathur P^1,2, Gross C^1,2, Eyasu R^1,2, Nussdorf L^2,3, Hill K^2,3, Brokus C^2,3, D'Amore A^2,3, Sidique N^2,3, Bijole P⁴, Jones M⁴, Kier R⁴, McCullough D⁴, Sternberg D⁴, Stafford K¹, Sun J³, Masur H^2,3, Kottilil S^1,2, Kattakuzhy S^1,2. Clin Infect Dis. 2020 Feb 3. pii: ciaa105. doi: 10.1093/cid/ciaa105. [Epub ahead of print]

234.	Quality improvement in hepatitis C screening and treatment in a primary care resident clinic
	Doering T¹, Williamson S¹, Gadalla M¹. J Community Hosp Intern Med Perspect. 2019 Dec 14;9(6):471-472. doi: 10.1080/20009666.2019.1698230. eCollection 2019.

235.	Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project
	Caven M¹, Robinson EM^1,2, Eriksen AJ³, Fletcher EH^1,3, Dillon JF^1,2. J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269. [Epub ahead of print]

236.	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection
	Scott N^1,2, Snell G³, Westall G³, Pilcher D^4,5, Raggatt M^6,7, Walker RG^8,9, Hellard M^6,4,7, Peleg AY^7,10, Doyle J^6,7. Sci Rep. 2020 Jan 29;10(1):1459. doi: 10.1038/s41598-020-58215-z.

237.	A Co-localized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
	Adamson PC¹, Miceli J², Shiferaw B³, Villaneuva MS², Canterino JE⁴. Am J Med. 2020 Jan 24. pii: S0002-9343(20)30039-5. doi: 10.1016/j.amjmed.2019.12.028. [Epub ahead of print]

238.	Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
	Niccum BA¹, Stine JG², Wynter JA³, Kelly V³, Caldwell SH³, Shah NL³. Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.

239.

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

Soria A¹, Fava M^1,2, Bernasconi DP³, Lapadula G¹, Colella E¹, Valsecchi MG³, Migliorino GM¹, D'Ambrosio R⁴, Landonio S⁵, Schiavini M⁵, Spinetti A⁶, Carriero C⁶, Degasperi E⁴, Cologni G⁷, Gatti F⁸, Viganò P⁸, Hasson H⁹, Uberti-Foppa C¹⁰, Pasulo L⁷, Baiguera C¹¹, Rossotti R¹¹, Vinci M¹¹, Puoti M¹¹, Giorgini A¹², Menzaghi B¹³, Lombardi A¹⁴, Pan A¹⁵, Aghemo A¹⁶, Grossi PA¹⁷, Boldizzoni R¹⁸, Colombo S¹⁸, Viganò M¹⁹, Rumi MG¹⁹, Del Poggio P²⁰, Valenti L²¹, Giglio O²², De Bona A¹², d'Arminio Monforte A¹², Colombo A²², Spinelli O²², Pigozzi MG⁶, Molteni C²³, Bonfanti P²³, Terreni N²⁴, Perini P²⁵, Capretti A²⁶, Bella D²⁷, Liani C²⁷, Polo S²⁷, Aimo G²⁷, Pagnucco L¹⁴, Bhoori S²⁸, Centenaro R²⁹, Graffeo M³⁰, Ciaccio A³¹, Dionigi E³², Lazzaroni S³³, Carderi I³⁴, Di Marco M³⁵, Rizzardini G⁵, Noventa F³⁶, Lampertico P⁴, Fagiuoli S⁷. Liver Int. 2020 Jan 22. doi: 10.1111/liv.14386. [Epub ahead of print]

240.	Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system
	Tapp H¹, Ludden T¹, Shade L¹, Thomas J¹, Mohanan S¹, Leonard M². Prev Med Rep. 2020 Jan 7;17:101036. doi: 10.1016/j.pmedr.2019.101036. eCollection 2020 Mar.

241.	Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment
	O'Keefe-Markman C¹, Lea KD², McCabe C^3,4, Hyshka E^1,5, Bubela T⁶. BMC Public Health. 2020 Jan 20;20(1):89. doi: 10.1186/s12889-020-8190-2.

242.	Effect of Needle Exchange Program on Maternal Hepatitis C Virus Prevalence
	Rossi RM^1,2, Brady MJ¹, Hall ES^3,4, Warshak CR^1,2. Am J Perinatol. 2020 Jan 21. doi: 10.1055/s-0039-3402753. [Epub ahead of print]

243.	Global prevalence of hepatitis C virus in children in 2018: a modelling study
	Schmelzer J¹, Dugan E¹, Blach S¹, Coleman S¹, Cai Z¹, DePaola M¹, Estes C¹, Gamkrelidze I¹, Jerabek K¹, Ma S¹, Montoya S¹, Razavi-Shearer D¹, Razavi-Shearer K¹, Robbins-Scott S¹, Razavi H², El Sayed MH³. Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30385-1. doi: 10.1016/S2468-1253(19)30385-1. [Epub ahead of print]

244.	Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials
	Poordad F¹, Castro RE², Asatryan A³, Aguilar H⁴, Cacoub P^5,6, Dieterich D⁷, Marinho RT⁸, Carvalho A⁹, Siddique A¹⁰, Hu YB¹¹, Charafeddine M¹², Bondin M¹¹, Khan N¹¹, Cohen DE¹¹, Felizarta F¹³. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]

245.	The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia
	Phillips M¹, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. Health Care Manag (Frederick). 2020 Jan/Mar;39(1):2-11. doi: 10.1097/HCM.0000000000000278.

246.	Management of Hepatitis C in the Older Adult
	Chahine EB, Guirguis EH, Derrick CB. Sr Care Pharm. 2020 Jan 1;35(1):13-28.

247.	Control of HCV Infection by Natural Killer Cells and Macrophages
	Rosen HR^1,2, Golden-Mason L^1,2. Cold Spring Harb Perspect Med. 2019 Dec 23. pii: a037101. doi: 10.1101/cshperspect.a037101. [Epub ahead of print]

248.	Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients
	Laub M¹, Harris M, Sanoff S, Berg C, Byrns J. Exp Clin Transplant. 2019 Dec 24. doi: 10.6002/ect.2019.0289. [Epub ahead of print]

249.	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment
	Palmer AY¹, Wade AJ², Draper B³, Howell J⁴, Doyle JS⁵, Petrie D⁶, Thompson AJ⁷, Wilson DP⁸, Hellard ME⁹, Scott N³. nt J Drug Policy. 2019 Dec 20;76:102633. doi: 10.1016/j.drugpo.2019.102633. [Epub ahead of print]

250.	Dynamic modeling of hepatitis C transmission among people who inject drugs
	Stocks T¹, Martin LJ², Kühlmann-Berenzon S², Britton T³. Epidemics. 2019 Dec 11;30:100378. doi: 10.1016/j.epidem.2019.100378. [Epub ahead of print]

251.	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
	Choi DT¹, Puenpatom A², Yu X¹, Erickson KF¹, Kanwal F³, El-Serag HB³, Kramer JR⁴. Antiviral Res. 2019 Dec 17;174:104698. doi: 10.1016/j.antiviral.2019.104698. [Epub ahead of print]

252.

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

Chen Q¹, Perales C¹, Soria ME², García-Cehic D¹, Gregori J³, Rodríguez-Frías F⁴, Buti M¹, Crespo J⁵, Calleja JL⁶, Tabernero D⁴, Vila M⁷, Lázaro F⁸, Rando-Segura A⁷, Nieto-Aponte L⁷, Llorens-Revull M¹, Cortese MF⁷, Fernandez-Alonso I², Castellote J⁹, Niubó J¹⁰, Imaz A¹¹, Xiol X⁹, Castells L¹, Riveiro-Barciela M¹, Llaneras J¹, Navarro J¹², Vargas-Blasco V¹, Augustin S¹, Conde I¹³, Rubín Á¹³, Prieto M¹³, Torras X¹⁴, Margall N¹⁵, Forns X¹⁶, Mariño Z¹⁶, Lens S¹⁶, Bonacci M¹⁷, Pérez-Del-Pulgar S¹⁶, Londoño MC¹⁶, García-Buey ML¹⁸, Sanz-Cameno P¹⁸, Morillas R¹⁹, Martró E²⁰, Saludes V²⁰, Masnou-Ridaura H¹⁹, Salmerón J²¹, Quíles R²¹, Carrión JA²², Forné M²³, Rosinach M²³, Fernández I²⁴, García-Samaniego J²⁵, Madejón A²⁵, Castillo-Grau P²⁶, López-Núñez C²⁷, Ferri MJ²⁸, Durández R²⁹, Sáez-Royuela F³⁰, Diago M³¹, Gimeno C³², Medina R³², Buenestado J³³, Bernet A³⁴, Turnes J³⁵, Trigo-Daporta M³⁶, Hernández-Guerra M³⁷, Delgado-Blanco M³⁸, Cañizares A³⁹, Arenas JI⁴⁰, Gomez-Alonso MJ⁶, Rodríguez M⁴¹, Deig E⁴², Olivé G⁴³, Río OD⁴³, Cabezas J⁵, Quiñones I⁴⁴, Roget M⁴⁵, Montoliu S⁴⁶, García-Costa J⁴⁷, Force L⁴⁸, Blanch S⁴⁹, Miralbés M⁵⁰, López-de-Goicoechea MJ⁵¹, García-Flores A⁵², Saumoy M¹¹, Casanovas T⁹, Baliellas C⁹, Gilabert P⁹, Martin-Cardona A⁹, Roca R⁹, Barenys M⁵³, Villaverde J⁹, Salord S⁹, Camps B⁹, Silvan di Yacovo M⁹, Ocaña I¹², Sauleda S⁵⁴, Bes M⁵⁴, Carbonell J², Vargas-Accarino E², Ruzo SP², Guerrero-Murillo M², Von Massow G², Costafreda MI⁵⁵, López RM⁷, González-Moreno L¹⁸, Real Y¹⁸, Acero-Fernández D²⁷, Viroles S²⁷, Pamplona X²⁷, Cairó M²³, Ocete MD³², Macías-Sánchez JF⁴³, Estébanez A⁵, Quer JC⁴⁶, Mena-de-Cea Á³⁸, Otero A³⁸, Castro-Iglesias Á³⁸, Suárez F³⁸, Vázquez Á³⁸, Vieito D³⁸, López-Calvo S³⁸, Vázquez-Rodríguez P³⁸, Martínez-Cerezo FJ⁵⁶, Rodríguez R⁴⁷, Macenlle R⁴⁷, Cachero A⁵⁷, Mereish G⁵⁷, Mora-Moruny C⁵⁸, Fábregas S⁵⁸, Sacristán B⁵⁹, Albillos A⁶⁰, Sánchez-Ruano JJ⁶¹, Baluja-Pino R⁶², Fernández-Fernández J⁶², González-Portela C⁶², García-Martin C⁶³, Sánchez-Antolín G⁶⁴, Andrade RJ⁶⁵, Simón MA⁶⁶, Pascasio JM⁶⁷, Romero-Gómez M⁶⁸, Antonio Del-Campo J⁶⁸, Domingo E⁶⁹, Esteban R¹, Esteban JI⁷⁰, Quer J⁷¹. Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]

253.	Cost burden of hepatitis C virus treatment in commercially insured patients
	Lu CY¹, Ross-Degnan D, Zhang F, LeCates R, Lupton C, Sherman M, Wagner A. Am J Manag Care. 2019 Dec 1;25(12):e379-e387.

254.	Expanding the use of hepatitis C positive donors and keeping recipient safety at the forefront
	Terrault NA¹, Sher L². Am J Transplant. 2019 Dec 15. doi: 10.1111/ajt.15745. [Epub ahead of print]

255.	Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C
	Schlendorf KH¹, Zalawadiya S¹, Shah AS¹, Perri R¹, Wigger M¹, Brinkley DM¹, Danter MR¹, Menachem JN¹, Punnoose LR¹, Balsara K¹, Sacks SB¹, Ooi H¹, Awad JA¹, Sandhaus E¹, Schwartz C¹, O'Dell H¹, Carver AB¹, Edmonds CL¹, Ruzevich-Scholl S¹, Lindenfeld J¹. JAMA Cardiol. 2019 Dec 18. doi: 10.1001/jamacardio.2019.4748. [Epub ahead of print]

256.	Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs
	Irvin R¹, Chander G¹, Ward KM¹, Manogue S¹, Falade-Nwulia O¹, Moon J¹, Sutcliffe CG², Brinkley S¹, Haselhuhn T¹, Katz S¹, Herne K¹, Arteaga L¹, Thomas DL¹, Mehta SH², Sulkowski MS¹. J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251. [Epub ahead of print]

257.	"Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy
	Jessop AB¹, Bass SB², Brajuha J², Alhajji M², Burke M³, Gashat MT³, Wellington C², Ventriglia N², Coleman J², D'Avanzo P². J Subst Abuse Treat. 2020 Feb;109:23-33. doi: 10.1016/j.jsat.2019.11.001. Epub 2019 Nov 6.

258.	Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study
	Ferguson TF^1,2, Rosen E^1,2, Carr R³, Brashear M^1,4, Simon L^1,5, Theall KP^1,4, Ronis MJ^1,6, Welsh DA^1,7, Molina PE^1,5. Alcohol Alcohol. 2019 Dec 8. pii: agz089. doi: 10.1093/alcalc/agz089. [Epub ahead of print]

259.	HCV Eradication: A Duty of the State, an Option for the Individual
	Craxì L^1,2. Adv Exp Med Biol. 2019 Dec 6. doi: 10.1007/5584_2019_452. [Epub ahead of print]

260.

Securing sustainable funding for viral hepatitis elimination plans

Hatzakis A¹, Lazarus JV², Cholongitas E³, Baptista-Leite R^4,5, Boucher C⁶, Busoi CS⁷, Deuffic-Burban S^8,9, Chhatwal J¹⁰, Esmat G^11,12, Hutchinson S^13,14, Malliori MM¹⁵, Maticic M^16,17, Mozalevskis A¹⁸, Negro F¹⁹, Papandreou GA²⁰, Papatheodoridis GV²¹, Peck-Radosavljevic M²², Razavi H²³, Reic T²⁴, Schatz E²⁵, Tozun N²⁶, Younossi Z²⁷, Manns MP²⁸. Liver Int. 2019 Dec 5. doi: 10.1111/liv.14282. [Epub ahead of print]

261.	Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma
	He S¹, Lockart I^2,3, Alavi M¹, Danta M^2,3, Hajarizadeh B¹, Dore GJ^1,3. Aliment Pharmacol Ther. 2020 Jan;51(1):34-52. doi: 10.1111/apt.15598. Epub 2019 Dec 6.

262.	Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
	Reilley B¹, Miller M², Hudson M³, Haverkate R², Leston J⁴. Int J Equity Health. 2019 Dec 4;18(1):190. doi: 10.1186/s12939-019-1101-4.

263.	HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience
	Kapila N^1,2, Menon KVN³, Al-Khalloufi K⁴, Vanatta JM⁴, Murgas C⁴, Reino D⁴, Ebaid S⁴, Shaw JJ⁴, Agrawal N⁴, Rhazouani S⁴, Navas V⁴, Sheffield C⁴, Rahman AU¹, Castillo M⁵, Miller C³, Quintini C³, Zervos XB⁴. Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011. [Epub ahead of print]

264.	Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy
	Ocal S¹, Muir AJ², Naggie S³. N C Med J. 2019 Nov-Dec;80(6):352-355. doi: 10.18043/ncm.80.6.352.

265.

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

Dietz J¹, Spengler U², Müllhaupt B³, Schulze Zur Wiesch J⁴, Piecha F⁴, Mauss S⁵, Seegers B⁶, Hinrichsen H⁶, Antoni C⁷, Wietzke-Braun P⁸, Peiffer KH¹, Berger A⁹, Matschenz K¹⁰, Buggisch P¹⁰, Backhus J¹¹, Zizer E¹¹, Boettler T¹², Neumann-Haefelin C¹², Semela D¹³, Stauber R¹⁴, Berg T¹⁵, Berg C¹⁶, Zeuzem S¹, Vermehren J¹, Sarrazin C¹⁷; European HCV Resistance Study Group. Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]

266.	Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis
	Lluch E¹, Miller BJ². Gen Hosp Psychiatry. 2019 Nov - Dec;61:41-46. doi: 10.1016/j.genhosppsych.2019.10.007. Epub 2019 Oct 23.

267.	The Elimination of Hepatitis C as a Public Health Threat
	Hellard M^1,2,3,4, Schroeder SE^1,2, Pedrana A^1,2, Doyle J^1,3, Aitken C^1,2. Cold Spring Harb Perspect Med. 2019 Nov 11. pii: a036939. doi: 10.1101/cshperspect.a036939. [Epub ahead of print]

268.	Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations
	Turner BJ¹, Rochat A², Lill S², Bobadilla R², Hernandez L², Choi A³, Guerrero JA⁴. Ann Intern Med. 2019 Dec 3. doi: 10.7326/M18-3573. [Epub ahead of print]

269.	Hepatitis C Virus Infection In Indigenous Populations: A Systematic Review Of The United States And Canada
	Bruce V¹, Eldredge J², Leyva Y³, Mera J⁴, English K⁵, Page K¹. Epidemiol Rev. 2019 Nov 29. pii: mxz015. doi: 10.1093/epirev/mxz015. [Epub ahead of print]

270.	Hepatitis C-Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012
	Hatcher SM^1,2, Joshi S², Robinson BF¹, Weiser T^2,3. Public Health Rep. 2020 Jan;135(1):66-73. doi: 10.1177/0033354919887748. Epub 2019 Nov 25.

271.	Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era
	Dupont SC¹, Fluker SA², Quairoli KM³, Body C⁴, Okosun I⁵, Lom J², Miller LS². Public Health Rep. 2020 Jan;135(1):107-113. doi: 10.1177/0033354919888228. Epub 2019 Nov 22.

272.	Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
	Boyle A^1,2, Marra F^1,2, Peters E³, Datta S⁴, Ritchie T⁵, Priest M⁶, Heydtmann M⁷, Barclay ST^8,9. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239. [Epub ahead of print]

273.	Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies
	Darvishian M^1,2,3,4, Wong S¹, Binka M¹, Yu A¹, Ramji A², Yoshida EM⁵, Wong J^1,2, Rossi C^1,2, Butt ZA^1,2, Bartlett S^1,2, Pearce ME^1,2, Samji H^1,6, Cook D¹, Alvarez M¹, Chong M¹, Tyndall M^1,2, Krajden M^1,2, Janjua NZ^1,2. J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]

274.	Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention
	Lanini S¹, Ustianowski A², Pisapia R³, Zumla A⁴, Ippolito G³. Infect Dis Clin North Am. 2019 Dec;33(4):1045-1062. doi: 10.1016/j.idc.2019.08.004.

275.	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore
	Hackman J¹, Falade-Nwulia O², Patel EU³, Mehta SH², Kirk GD⁴, Astemborski J², Ray SC⁵, Thomas DL⁴, Laeyendecker O⁶. Infect Genet Evol. 2019 Oct 24;77:104078. doi: 10.1016/j.meegid.2019.104078. [Epub ahead of print]

276.	Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis Ctreatment for people who inject drugs: The HERO study
	Litwin AH¹, Jost J², Wagner K³, Heo M⁴, Karasz A⁵, Feinberg J⁶, Kim AY⁷, Lum PJ⁸, Mehta SH⁹, Taylor LE¹⁰, Tsui JI¹¹, Pericot-Valverde I¹², Page K³; HERO Study Group. Contemp Clin Trials. 2019 Dec;87:105859. doi: 10.1016/j.cct.2019.105859. Epub 2019 Oct 24.

277.	A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
	Radley A^1,2, Robinson E³, Aspinall EJ⁴, Angus K⁵, Tan L³, Dillon JF³. BMC Health Serv Res. 2019 Oct 28;19(1):765. doi: 10.1186/s12913-019-4635-7.

278.	Provision of and Barriers to Integrating Reproductive and Sexual Health Services for Reproductive-age Women in Opioid Treatment Programs
	Klaman SL¹, Lorvick J, Jones HE. J Addict Med. 2019 Nov/Dec;13(6):422-429. doi: 10.1097/ADM.0000000000000519.

279.

Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study

Bajis S¹, Grebely J¹, Hajarizadeh B¹, Applegate T¹, Marshall AD^1,2, Harrod ME³, Byrne J⁴, Bath N³, Read P⁵, Edwards M⁶, Gorton C⁷, Hayllar J⁸, Cock V⁹, Peterson S¹⁰, Thomson C¹¹, Weltman M¹², Jefferies M¹³, Wood W¹⁴, Haber P¹⁵, Ezard N^16,17, Martinello M¹, Maher L^1,18, Dore GJ¹; LiveRLife Study Group. J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]

280.	Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
	Struble K¹, Chan-Tack K¹, Qi K², Valappil T², Connelly S¹, Mishra P¹, Price D², Murray J¹, Birnkrant D¹. J Virus Erad. 2019 Sep 18;5(3):138-144.

281.	Nurse practitioner interventions for smokers with chronic hepatitis C
	Reid C¹, Fenech M², Jones L³, Salehi N⁴. J Am Assoc Nurse Pract. 2019 Nov 5. doi: 10.1097/JXX.0000000000000311. [Epub ahead of print]

282.	Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England
	Williams J¹, Miners A², Harris R³, Mandal S⁴, Simmons R⁴, Ireland G⁴, Hickman M⁵, Gore C⁶, Vickerman P⁷. Value Health. 2019 Nov;22(11):1248-1256. doi: 10.1016/j.jval.2019.06.006. Epub 2019 Aug 19.

283.	Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation
	Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014. [Epub ahead of print]

284.	Motivation to Quit Drinking in Individuals Coinfected with HIV and Hepatitis C
	Hayaki J¹, Anderson BJ², Herman DS^2,3, Moitra E³, Pinkston MM^3,4, Kim HN^5,6, Stein MD⁷. AIDS Behav. 2019 Oct 23. doi: 10.1007/s10461-019-02709-z. [Epub ahead of print]

285.	Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States
	Pan CQ^1,2, Gayam V³, Rabinovich C⁴, Normatov M⁴, Fidman B⁴, Wang D⁵, Garlapati P³. J Am Geriatr Soc. 2019 Oct 24. doi: 10.1111/jgs.16206. [Epub ahead of print]

286.	HCV in the Hemodialysis Population: treat now or later?
	Martin P¹, Jadoul M², Pol S³. J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224. [Epub ahead of print]

287.	Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
	Page K^1,2, Qeadan F^1,2, Qualls C², Thornton K¹, Arora S¹. Hepat Med. 2019 Oct 7;11:149-152. doi: 10.2147/HMER.S212855. eCollection 2019.

288.	The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy
	McDowell ML¹, Tonismae TR¹, Slaven JE², Abernathy MP¹, Shanks AL¹, Benjamin TD³, Quinney SK¹. Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838. [Epub ahead of print]

289.	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals
	Serper M¹, Evon DM², Stewart PW³, Lok AS⁴, Amador J³, Reeve BB⁵, Golin CE⁶, Fried MW⁷, Reddy KR¹, Sterling RK⁸, Sarkar S⁹, Di Bisceglie AM¹⁰, Lim JK¹¹, Nelson DR¹², Reau N¹³. J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]

290.

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy

Cunningham EB¹, Hajarizadeh B¹, Amin J^1,2, Litwin AH^3,4,5, Gane E⁶, Cooper C⁷, Lacombe K⁸, Hellard M^9,10, Read P^1,11, Powis J¹², Dalgard O^13,14, Bruneau J¹⁵, Matthews GV^1,16, Feld JJ¹⁷, Dillon JF¹⁸, Shaw D¹⁹, Bruggmann P²⁰, Conway B²¹, Fraser C²², Marks P¹, Dore GJ^1,16, Grebely J¹. Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]

291.	Characteristics and current clinical practices of opioid treatment programs in the United States
	Jones CM¹, Byrd DJ², Clarke TJ³, Campbell TB², Ohuoha C⁴, McCance-Katz EF⁵. Drug Alcohol Depend. 2019 Oct 17;205:107616. doi: 10.1016/j.drugalcdep.2019.107616. [Epub ahead of print]

292.

Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial

Brown RS Jr¹, Buti M², Rodrigues L³, Chulanov V⁴, Chuang WL⁵, Aguilar H⁶, Horváth G⁷, Zuckerman E⁸, Carrion BR⁹, Rodriguez-Perez F¹⁰, Urbánek P¹¹, Abergel A¹², Cohen E³, Lovell SS³, Schnell G³, Lin CW³, Zha J³, Wang S³, Trinh R³, Mensa FJ³, Burroughs M³, Felizarta F¹³. J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]

293.	The role of stigma and trauma in hepatitis C virus treatment in veterans: Applying the common-sense model
	Garvey CM¹, Jones R¹. Public Health Nurs. 2019 Nov;36(6):829-835. doi: 10.1111/phn.12665. Epub 2019 Oct 3.

294.	Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost
	Perfect C¹, Jhaveri R^2,3. J Pediatric Infect Dis Soc. 2019 Oct 16. pii: piz069. doi: 10.1093/jpids/piz069. [Epub ahead of print]

295.	A Simplified Algorithm for the Management of Hepatitis C Infection
	Dieterich DT¹. Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 3):1-12.

296.	Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age
	McCabe P¹, Galoosian A², Wong RJ³. Dig Dis Sci. 2019 Oct 22. doi: 10.1007/s10620-019-05891-1. [Epub ahead of print]

297.	Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI?=?1 in a Single-Arm, Open-Label, Multicenter Study.
	Fontana RJ¹, Lens S², McPherson S³, Elkhashab M⁴, Ankoma-Sey V⁵, Bondin M⁶, Dos Santos AGP⁶, Xue Z⁶, Trinh R⁶, Porcalla A⁶, Zeuzem S⁷. Adv Ther. 2019 Oct 23. doi: 10.1007/s12325-019-01123-0. [Epub ahead of print]

298.	Hepatitis C Screening: Barriers to Linkage to Care
	Saab S^1,2, Challita YP¹, Najarian LM¹, Guo R³, Saggi SS¹, Choi G^1,2. J Clin Transl Hepatol. 2019 Sep 28;7(3):226-231. doi: 10.14218/JCTH.2018.00063. Epub 2019 Apr 12.

299.	Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment
	Daniel KE^1,2, Saeian K¹, Rizvi S¹. J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218. [Epub ahead of print]

300.	Electronic Clinical Decision Support Intervention to Increase Hepatitis C Screening and Linkage to Care Among Baby Boomers in Urban Safety Net Health Systems
	Armstrong H¹, Gonzalez-Drigo M¹, Norels G¹, Taussig D¹, Trick W², Diep L², Zhang H², Catrambone JC¹, Adeyemi O¹. Popul Health Manag. 2019 Oct 8. doi: 10.1089/pop.2019.0105. [Epub ahead of print]

301.	Medical Burden of Disease Among Individuals in Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National Recovery Survey
	Eddie D¹, Greene MC, White WL, Kelly JF. J Addict Med. 2019 Sep/Oct;13(5):385-395. doi: 10.1097/ADM.0000000000000512.

302.	Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma
	Singal AK¹, Satapathy SK², Reau N², Wong R², Kuo YF². Dig Liver Dis. 2019 Sep 30. pii: S1590-8658(19)30785-6. doi: 10.1016/j.dld.2019.08.022. [Epub ahead of print]

303.

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol)

Hickman M¹, Dillon JF², Elliott L³, De Angelis D⁴, Vickerman P⁵, Foster G^6,7, Donnan P⁸, Eriksen A⁹, Flowers P³, Goldberg D^3,10, Hollingworth W⁵, Ijaz S¹¹, Liddell D¹², Mandal S¹¹, Martin N¹³, Beer LJZ¹⁴, Drysdale K^6,7, Fraser H⁵, Glass R¹¹, Graham L¹⁵, Gunson RN¹⁶, Hamilton E¹⁷, Harris H¹¹, Harris M¹⁸, Harris R¹¹, Heinsbroek E¹¹, Hope V¹⁹, Horwood J⁵, Inglis SK¹⁴, Innes H^3,10, Lane A⁵, Meadows J⁵, McAuley A^3,10, Metcalfe C⁵, Migchelsen S¹¹, Murray A¹⁷, Myring G⁵, Palmateer NE^3,10, Presanis A⁴, Radley A^2,20, Ramsay M¹¹, Samartsidis P⁴, Simmons R¹¹, Sinka K¹¹, Vojt G³, Ward Z⁵, Whiteley D²¹, Yeung A^3,10, Hutchinson SJ^3,10. BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.

304.	Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016
	Zou B¹, Yeo YH¹, Le MH¹, Henry L¹, Chang ET^2,3, Lok AS⁴, Cheung R^1,5, Nguyen MH¹. J Infect Dis. 2019 Sep 27. pii: jiz479. doi: 10.1093/infdis/jiz479. [Epub ahead of print]

305.	Eradicating hepatitis C virus: The APRN
	Pozza R¹, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c.

306.	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials
	Brown A¹, Welzel TM², Conway B³, Negro F⁴, Bräu N⁵, Grebely J⁶, Puoti M⁷, Aghemo A⁸, Kleine H⁹, Pugatch D¹⁰, Mensa FJ¹⁰, Chen YJ¹⁰, Lei Y¹⁰, Lawitz E¹¹, Asselah T¹². Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]

307.	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy
	Lazarus JV¹, Roel E^1,2, Elsharkawy AM³. Cold Spring Harb Perspect Med. 2019 Sep 30. pii: a036913. doi: 10.1101/cshperspect.a036913. [Epub ahead of print]

308.	Challenges and Promise of a Hepatitis C Virus Vaccine
	Cox AL¹. Cold Spring Harb Perspect Med. 2019 Sep 23. pii: a036947. doi: 10.1101/cshperspect.a036947. [Epub ahead of print]

309.	"That Can't Be!": Perceptions of HIV and Hepatitis C Screening during Admission to an Acute Care Surgery Service
	Privette AR¹, Ferguson PL¹, Olsen J¹, Gay S¹, Richey LE². J Emerg Trauma Shock. 2019 Jul-Sep;12(3):185-191. doi: 10.4103/JETS.JETS_103_18.

310.	Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection
	Millman AJ¹, Luo Q², Nelson NP¹, Vellozzi C¹, Weiser J³. AIDS Care. 2019 Sep 23:1-9. doi: 10.1080/09540121.2019.1668533. [Epub ahead of print]

311.	Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
	Huff J¹, Andersen R¹. Ann Pharmacother. 2019 Sep 19:1060028019877128. doi: 10.1177/1060028019877128. [Epub ahead of print]

312.	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
	Gordon CE¹, Berenguer MC², Doss W³, Fabrizi F⁴, Izopet J⁵, Jha V⁶, Kamar N⁷, Kasiske BL⁸, Lai CL⁹, Morales JM¹⁰, Patel PR¹¹, Pol S¹², Silva MO¹³, Balk EM¹⁴, Earley A¹⁵, Di M¹⁶, Cheung M¹⁵, Jadoul M¹⁷, Martin P¹⁸. Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]

313.	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination
	Scott N^1,2, Wilson DP^3,4, Thompson AJ^5,6, Barnes E^7,8, El-Sayed M⁹, Benzaken AS¹⁰, Drummer HE^3,11,12, Hellard ME^3,4,12,13. BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.

314.	Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis
	Graf C¹, Mücke MM¹, Dultz G¹, Peiffer KH¹, Kubesch A¹, Ingiliz P², Zeuzem S¹, Herrmann E³, Vermehren J¹. Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]

315.	Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care
	Abe CM¹, Aguwa M², Zhao M², Sullivan J³, Porsa E³, Nijhawan AE⁴. Public Health Rep. 2019 Sep 17:33354919874081. doi: 10.1177/0033354919874081. [Epub ahead of print]

316.	Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
	Cotter TG¹, Jensen DM². Drug Des Devel Ther. 2019 Jul 29;13:2565-2577. doi: 10.2147/DDDT.S172512. eCollection 2019.

317.	Hepatitis C Treatment Cascade in a Federally Qualified Health Center
	Hachey DM¹, Holmes JT², Aubuchon-Endsley NL³. J Community Health. 2019 Sep 11. doi: 10.1007/s10900-019-00736-4. [Epub ahead of print]

318.	Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-?G and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy
	Emmanuel B¹, El-Kamary SS², Magder LS², Stafford KA^1,2, Charurat ME³, Chairez C⁴, McLaughlin M⁴, Hadigan C⁴, Prokunina-Olsson L⁵, O'Brien TR⁵, Masur H⁶, Kottilil S¹. J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]

319.	Defining the hepatitis C cure cascade in an Urban health system using the electronic health record
	Miller LS¹, Millman AJ², Lom J¹, Osinubi A², Ahmed F³, Dupont S¹, Rein D³, Vellozzi C², Harris AM². J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]

320.

Defining the hepatitis C cure cascade in an Urban health system using the electronic health record

Miller LS¹, Millman AJ², Lom J¹, Osinubi A², Ahmed F³, Dupont S¹, Rein D³, Vellozzi C², Harris AM². J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]

321.	Hepatitis C Virus: 30 Years after Its Discovery
	Houghton M¹. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]

322.	HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
	Cooper CL^1,2,3, Galanakis C⁴, Donelle J⁵, Kwong J^5,6,7, Boyd R⁸, Boucher L⁹, Kendall CE^4,5,9,10,11. BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6.

323.	Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia
	Baker LS¹, Smith W², Gulley T³, Tomann MM². J Community Health. 2019 Sep 9. doi: 10.1007/s10900-019-00732-8. [Epub ahead of print]

324.	Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care
	McMahon BJ^1,2, Townshend-Bulson L¹, Homan C¹, Gounder P², Barbour Y¹, Hewitt A¹, Bruden D², Espera H¹, Plotnik J¹, Gove J¹, Stevenson TJ¹, Luna SV¹, Simons BC^1,2. Clin Infect Dis. 2019 Aug 28. pii: ciz832. doi: 10.1093/cid/ciz832. [Epub ahead of print]

325.	Hepatitis C Virus: 30 Years after Its Discovery
	Houghton M¹. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]

326.	Hepatitis C Virus Structure: Defined by What It Is Not
	Dearborn AD^1,2, Marcotrigiano J¹. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a036822. doi: 10.1101/cshperspect.a036822. [Epub ahead of print]

327.	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV
	Saeed S^1,2, Strumpf E^1,3, Moodie EEM¹, Wong L², Cox J^1,2, Walmsley S^4,5, Tyndall M⁶, Cooper C^5,7, Conway B⁸, Hull M^5,9, Martel-Laferriere V¹⁰, Gill J¹¹, Wong A¹², Vachon ML¹³, Klein MB^2,5; Canadian Co-Infection Cohort Study Investigators. Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]

328.	Screening for Chronic Hepatitis C Virus: Occupational Health Nurses Interpreting the Titers
	Cadet MJ¹. Workplace Health Saf. 2019 Sep;67(9):495-496. doi: 10.1177/2165079919865560.

329.	Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection
	Mohanty A¹, Salameh S², Butt AA^3,4,5,6. Curr HIV/AIDS Rep. 2019 Sep 4. doi: 10.1007/s11904-019-00466-1. [Epub ahead of print]

330.	Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
	Ferrari SM¹, Fallahi P², Ruffilli I¹, Elia G¹, Ragusa F¹, Paparo SR¹, Patrizio A¹, Mazzi V¹, Colaci M³, Giuggioli D⁴, Ferri C⁴, Antonelli A¹. J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.

331.	Hepatitis C Core-Antigen Testing from Dried Blood Spots
	Biondi MJ^1,2,3, van Tilborg M^4,5, Smookler D^6,7, Heymann G⁸, Aquino A⁹, Perusini S¹⁰, Mandel E^11,12, Kozak RA¹³, Cherepanov V¹⁴, Kowgier M¹⁵, Hansen B^16,17, Goneau LW¹⁸, Janssen HLA^19,20, Mazzulli T^21,22, Cloherty G²³, de Knegt RJ²⁴, Feld JJ^25,26,27. Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.

332.	The Cost Effectiveness of Birth-Cohort Hepatitis C Screening During Pre-Admission Testing for Elective Procedures at a Single Specialty Orthopedic Hospital
	Sibley RA, Pham V, Moynihan AM, Hutzler LH, Bosco JA. Bull Hosp Jt Dis (2013). 2019 Sep;77(3):206-210.

333.	Technology preferences to enhance HIV and HCV care among patients with substance use disorders
	Tofighi B^1,2,3, Hein P¹, Carvalho AMS⁴, Lee JD^1,2,3, Leonard NR^3,5. J Addict Dis. 2019 Aug 5:1-3. doi: 10.1080/10550887.2019.1640056. [Epub ahead of print]

334.	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study
	Trickey A^1,2, Fraser H¹, Lim AG¹, Walker JG¹, Peacock A³, Colledge S³, Leung J^3,4,5, Grebely J^5,6, Larney S³, Martin NK^1,7, Degenhardt L³, Hickman M^1,2, May MT^1,2,8, Vickerman P^1,2. J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187. [Epub ahead of print]

335.	Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
	Pedlar A¹, Sandhu PJ¹. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]

336.	Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
	Moorman AC¹, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.

337.	Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study
	Lee KK¹, Stelzle D², Bing R¹, Anwar M¹, Strachan F¹, Bashir S¹, Newby DE¹, Shah JS³, Chung MH³, Bloomfield GS⁴, Longenecker CT⁵, Bagchi S⁶, Kottilil S⁶, Blach S⁷, Razavi H⁷, Mills PR⁸, Mills NL⁹, McAllister DA¹⁰, Shah ASV¹¹. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.

338.	We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade
	Lazarus JV¹, Pericàs JM², Picchio C¹, Cernosa J³, Hoekstra M¹, Luhmann N⁴, Maticic M^5,6, Read P⁷, Robinson EM⁸, Dillon JF⁸. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]

339.	Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
	Moorman AC¹, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.

340.	No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
	Rutledge SM^1,2, Zheng H², Li DK^1,2, Chung RT^1,2. Hepatoma Res. 2019;5. pii: 31. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.

341.	Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis
	Kwo PY¹, Puenpatom A², Zhang Z³, Hui SL⁴, Kelley AA⁵, Muschi D⁶. PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.

342.	Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study
	Weinstein AA¹, Estep JM², de Avila L², Curry M³, Golabi P², Escheik C², Birerdinc A², Stepanova M⁴, Price JK², Gerber L⁵, Younossi ZM⁶. J Neuroimmunol. 2019 Oct 15;335:577022. doi: 10.1016/j.jneuroim.2019.577022. Epub 2019 Aug 14.

343.	Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection
	DeCarolis DD¹, Chen YC², Westanmo AD³, Conley C⁴, Gravely AA⁵, Khan FB⁶. Am J Health Syst Pharm. 2019 Sep 1;76(17):1273-1280. doi: 10.1093/ajhp/zxz127.

344.	Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
	Pedlar A¹, Sandhu PJ¹. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]

345.	Infectious complications of addiction: A call for a new subspecialty within infectious diseases
	Serota DP¹, Barocas JA^2,3, Springer SA⁴. Clin Infect Dis. 2019 Aug 17. pii: ciz804. doi: 10.1093/cid/ciz804. [Epub ahead of print]

346.	Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
	Moorman AC¹, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.

347.	Short-Term Outcomes and Lessons Learned From the Federal HIV Health Improvement Affinity Group for State Medicaid/Children
	Davies C¹, Klein PW², Okoye ID³, Heitgerd J⁴, Shapatava E⁴, Ihiasota I⁴, Browne MNC⁵, Viall A⁶, Stockmann D⁵, Hauck H⁷. J Acquir Immune Defic Syndr. 2019 Sep 1;82 Suppl 1:S62-S68. doi: 10.1097/QAI.0000000000002021.

348.	Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population
	Stevens ER^1,2, Nucifora KA¹, Hagan H^2,3, Jordan AE^3,4, Uyei J¹, Khan B⁵, Dombrowski K⁵, des Jarlais D², Braithwaite RS^1,3. Clin Infect Dis. 2019 Aug 11. pii: ciz726. doi: 10.1093/cid/ciz726. [Epub ahead of print]

349.	Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply
	Mooney JJ¹, Purington N², Mohabir P¹, Dhillon GS¹. Am J Transplant. 2019 Aug 8. doi: 10.1111/ajt.15558. [Epub ahead of print]

350.	Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals
	Ioannou GN^1,2, Green PK², Berry K², Graf SA^3,4. Hepatol Commun. 2019 Jun 11;3(8):1124-1136. doi: 10.1002/hep4.1389. eCollection 2019 Aug.

351.	Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy
	Lok AS¹, Sulkowski MS², Kort JJ³, Willner I⁴, Reddy KR⁵, Shiffman ML⁶, Hassan MA⁷, Pearlman BL⁸, Hinestrosa F⁹, Jacobson IM¹⁰, Morelli G¹¹, Peter JA¹², Vainorius M¹³, Michael LC¹⁴, Fried MW¹⁵, Wang GP¹⁶, Lu W¹⁷, Larsen L¹⁸, Nelson DR¹⁹. Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]

352.	Direct-Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
	Simoes CC¹, Saldarriaga OA¹, Utay NS², Stueck AE³, Merwat SK⁴, Merwat SN⁴, Schiano TD⁵, Fiel MI⁶, Stevenson HL¹. Hepatol Commun. 2019 Jun 8;3(8):1113-1123. doi: 10.1002/hep4.1388. eCollection 2019 Aug.

353.	What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism
	Mattingly TJ 2nd¹, Slejko JF², Perfetto EM^2,3, Kottilil S⁴, Mullins CD². Patient. 2019 Jul 26. doi: 10.1007/s40271-019-00378-7. [Epub ahead of print]

354.

Advancing Public Health in Indian Country for Over 20 Years:S97-S100. doi: 10.1097/PHH.0000000000001061

An Evaluation of Hepatitis C Virus Telehealth Services Serving Tribal Communities: Patterns of Usage, Evolving Needs, and Barriers.

Stephens D¹, Leston J, Terrault NA, Gailloux K, Mera J, Essex W, Reilley B. J Public Health Manag Pract. 2019 Sep/Oct;25 Suppl 5, Tribal Epidemiology Centers:

355.	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all
	Grebely J¹, Hajarizadeh B², Lazarus JV³, Bruneau J⁴, Treloar C⁵; International Network on Hepatitis in Substance Users. Int J Drug Policy. 2019 Jul 23. pii: S0955-3959(19)30194-X. doi: 10.1016/j.drugpo.2019.07.016. [Epub ahead of print]

356.	Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department
	Hutton J¹, Doyle J², Zordan R³, Weiland T³, Cocco A⁴, Howell J⁵, Iser S⁶, Snell J⁷, Fry S⁸, New K⁸, Sloane R⁸, Jarman M⁷, Phan D⁷, Tran S⁷, Pedrana A⁹, Williams B⁹, Johnson J¹⁰, Glasgow S⁸, Thompson A⁷. Int J Drug Policy. 2019 Jul 24. pii: S0955-3959(19)30176-8. doi: 10.1016/j.drugpo.2019.06.021. [Epub ahead of print]

357.	The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination
	Safreed-Harmon K¹, Blach S², Aleman S^3,4, Boe Kielland K⁵, Bollerup S⁶, Cooke G⁷, Dalgard O^8,9, Dillon JF¹⁰, Dore GJ¹¹, Duberg AS¹², Grebely J¹¹, Midgard H¹³, Porter K¹⁴, Razavi H², Tyndall M¹⁵, Weis N^6,16, Lazarus JV^1,17. Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]

358.	Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort
	Macken L^1,2, Gelson W³, Priest M⁴, Abouda G⁵, Barclay S^4,6, Fraser A⁷, Healy B⁸, Irving W⁹, Verma S^1,2. J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552. [Epub ahead of print]

359.	Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
	Rentsch CT^1,2, Edelman EJ^3,4, Justice AC^5,3,4, Marshall BDL⁶, Xu K⁷, Smith AH⁷, Crystal S⁸, Gaither JR^9,10, Gordon AJ¹¹, Smith RV¹², Kember RL^13,14, Polimanti R⁷, Gelernter J^7,15, Fiellin DA^3,4, Tate JP^5,3, Kranzler HR^14,16, Becker WC^3,10; VACS Project Team. AIDS Behav. 2019 Jul 17. doi: 10.1007/s10461-019-02608-3. [Epub ahead of print]

360.	Maternal hepatitis B or C status and the long-term risk of gastrointestinal morbidity for offspring: A population-based cohort study
	Yoles I^1,2, Sheiner E², Abu-Freha N³, Wainstock T⁴. Liver Int. 2019 Jul 18. doi: 10.1111/liv.14193. [Epub ahead of print]

361.	Evidence-making hepatitis C cure: Towards a science that knows more carefully
	Rhodes T¹, Lancaster K². Int J Drug Policy. 2019 Jul 12. pii: S0955-3959(19)30178-1. doi: 10.1016/j.drugpo.2019.06.023. [Epub ahead of print]

362.	Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance
	Kimble MM¹, Javanbakht M², Chew KW¹, Stafylis C³, He D², Ramirez S⁴, Baik Y², Saab S⁴, Klausner JD^1,2. BMC Infect Dis. 2019 Jul 15;19(1):626. doi: 10.1186/s12879-019-4223-9.

363.	Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs
	Barbosa C¹, Fraser H², Hoerger TJ¹, Leib A³, Havens JR⁴, Young A⁴, Kral A¹, Page K⁵, Evans J⁶, Zibbell J¹, Hariri S⁷, Vellozzi C⁸, Nerlander L⁷, Ward JW⁷, Vickerman P². Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]

364.	Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies
	Gardenier D¹, Woody A², Amory C³, Weiss JJ⁴. Arch Psychiatr Nurs. 2019 Aug;33(4):352-357. doi: 10.1016/j.apnu.2019.02.001. Epub 2019 Feb 11.

365.	Hepatitis C Screening in Mothers and Infants Exposed to Opioids
	Bell R¹, Wolfe I², Cox D³, Thakarar K³, Lucas L³, Craig A³. Hosp Pediatr. 2019 Aug;9(8):639-642. doi: 10.1542/hpeds.2018-0225. Epub 2019 Jul 10.

366.	Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
	Herr MM¹, Schonfeld SJ¹, Dores GM^1,2, Engels EA³, Tucker MA⁴, Curtis RE¹, Morton LM¹. Blood Adv. 2019 Jul 9;3(13):1961-1969. doi: 10.1182/bloodadvances.2019030924.

367.	The remarkable history of the hepatitis C virus
	Pol S¹, Lagaye S². Microbes Infect. 2019 Jul 8. pii: S1286-4579(19)30068-1. doi: 10.1016/j.micinf.2019.06.008. [Epub ahead of print]

368.	The Role of Zinc in Antiviral Immunity
	Read SA^1,2, Obeid S³, Ahlenstiel C³, Ahlenstiel G^1,2. Adv Nutr. 2019 Jul 1;10(4):696-710. doi: 10.1093/advances/nmz013.

369.	Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders
	Boglione L¹, Lupia T², Cariti G², Di Perri G². J Infect Chemother. 2019 Jul 10. pii: S1341-321X(19)30173-4. doi: 10.1016/j.jiac.2019.06.004. [Epub ahead of print]

370.	Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study
	Lanini S¹, Bartolini B¹, Taibi C¹, Agresta A¹, Garbuglia AR¹, Montaldo C¹, Pisapia R¹, D'Offizi G¹, Scognamiglio P¹, Capobianchi MR¹, Zumla A², Ippolito G¹. New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]

371.	Exploring the emotions of patients undergoing therapy for hepatitis C
	Montague S¹, Agarwal K², Cannon M³. Br J Nurs. 2019 Jul 11;28(13):824-828. doi: 10.12968/bjon.2019.28.13.824.

372.	HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
	Chehl N¹, Maheshwari A, Yoo H, Cook C, Zhang T, Brown S, Thuluvath PJ. Medicine (Baltimore). 2019 Jul;98(28):e16242. doi: 10.1097/MD.0000000000016242.

373.	HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
	Mittal A¹, Kosinski KC², Stopka TJ³. Harm Reduct J. 2019 Jul 9;16(1):44. doi: 10.1186/s12954-019-0314-6.

374.	Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
	Crowley D^1,2, Murtagh R³, Cullen W³, Keevans M⁴, Laird E⁵, McHugh T⁶, McKiernan S⁷, Miggin SJ⁷, O'Connor E^3,6, O'Reilly D⁴, Betts-Symonds G⁸, Tobin C⁹, Van Hout MC¹⁰, Lambert JS^3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.

375.	HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center
	Calner P¹, Sperring H², Ruiz-Mercado G³, Miller NS⁴, Andry C⁴, Battisti L⁵, Scrudder K³, Shea F³, Chan A³, Schechter-Perkins EM¹. PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.

376.	A Decade On: Systematic Review of ClinicalTrials.gov Infectious Disease Trials, 2007-2017
	Jaffe IS¹, Chiswell K², Tsalik EL¹. Open Forum Infect Dis. 2019 Apr 15;6(6):ofz189. doi: 10.1093/ofid/ofz189. eCollection 2019 Jun.

377.	Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States
	Gordon S¹, Lee J², Smith N³, Dieterich D⁴. Expert Rev Pharmacoecon Outcomes Res. 2019 Jun 17:1-7. doi: 10.1080/14737167.2019.1629291. [Epub ahead of print]

378.	Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
	Crowley D^1,2, Murtagh R³, Cullen W³, Keevans M⁴, Laird E⁵, McHugh T⁶, McKiernan S⁷, Miggin SJ⁷, O'Connor E^3,6, O'Reilly D⁴, Betts-Symonds G⁸, Tobin C⁹, Van Hout MC¹⁰, Lambert JS^3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.

379.	Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
	Nolen LD¹, Gustin C², Seeman S¹, Murphy N², Truitt S², Schillie S³, Bruce MG¹, Bruden D¹, Tiesinga J⁴, McMahon B⁴. Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741. doi: 10.1155/2019/8654741. eCollection 2019.

380.	Overdose Deaths and Acute Hepatitis Infections among American Indians in North Carolina
	Cox ME¹, Dzialowy N², Armstrong L³, Proescholdbell S⁴. N C Med J. 2019 Jul-Aug;80(4):197-203. doi: 10.18043/ncm.80.4.197.

381.	The Massachusetts Hepatitis C Testing Cascade, 2014-2016
	Vo QT¹, Onofrey S¹, Church D¹, Cranston K¹, DeMaria A¹, Klevens RM¹. Microbiol Insights. 2019 Jun 21;12:1178636119857961. doi: 10.1177/1178636119857961. eCollection 2019.

382.	Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection
	Stevenson TJ¹, Barbour Y¹, McMahon BJ¹, Townshend-Bulson L¹, Hewitt AM¹, Espera HGF¹, Homan C¹, Holck P¹, Luna SV¹, Knall C², Simons BC^1,2. Open Forum Infect Dis. 2019 May 17;6(6):ofz223. doi: 10.1093/ofid/ofz223. eCollection 2019 Jun.

383.	Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals
	Bryant J¹, Rance J², Hull P³, Mao L⁴, Treloar C⁵. Int J Drug Policy. 2019 Jun 17. pii: S0955-3959(19)30157-4. doi: 10.1016/j.drugpo.2019.06.002. [Epub ahead of print]

384.	Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection
	Read P^1,2, Gilliver R¹, Kearley J¹, Lothian R¹, Cunningham EB², Chronister KJ¹, Dore GJ². J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175. [Epub ahead of print]

385.	Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
	Schwarz KB¹, Rosenthal P², Murray KF³, Honegger JR⁴, Hardikar W⁵, Hague R⁶, Mittal N⁷, Massetto B⁸, Brainard DM⁸, Hsueh CH⁸, Shao J⁸, Parhy B⁸, Narkewicz MR⁹, Rao GS¹⁰, Whitworth S¹¹, Bansal S¹², Balistreri WF¹³. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830. [Epub ahead of print]

386.	A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C has a Large Impact on Medical Plan Costs
	Leung N¹, Bernacki SE, Bernacki EJ. J Occup Environ Med. 2019 Jun 13. doi: 10.1097/JOM.0000000000001633. [Epub ahead of print]

387.	Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid
	Roebuck MC¹, Liberman JN. Am J Manag Care. 2019 Jun;25(8 Suppl):S131-S139.

388.

Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs

Llaneras J¹, Riveiro-Barciela M², Lens S³, Diago M⁴, Cachero A⁵, García-Samaniego J⁶, Conde I⁷, Arencibia A⁸, Arenas J⁹, Gea F¹⁰, Torras X¹¹, Luis Calleja J¹², Antonio Carrión J¹³, Fernández I¹⁴, María Morillas R¹⁵, Miguel Rosales J¹⁶, Carmona I¹⁷, Fernández-Rodríguez C¹⁸, Hernández-Guerra M¹⁹, Llerena S²⁰, Bernal V²¹, Turnes J²², González-Santiago JM²³, Montoliu S²⁴, Figueruela B²⁵, Badia E²⁶, Delgado M²⁷, Fernández-Bermejo M²⁸, Iñarrairaegui M²⁹, Manuel Pascasio J³⁰, Esteban R², Mariño Z³, Buti M³¹. J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]

389.	Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection
	Williams N¹, Bossert N¹, Chen Y², Jaanimägi U¹, Markatou M³, Talal AH⁴. J Subst Abuse Treat. 2019 Jul;102:33-39. doi: 10.1016/j.jsat.2019.04.009. Epub 2019 May 2.

390.	Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens
	Kimble MM¹, Stafylis C², Treut P¹, Saab S³, Klausner JD⁴. Diagn Microbiol Infect Dis. 2019 May 25. pii: S0732-8893(19)30117-8. doi: 10.1016/j.diagmicrobio.2019.05.010. [Epub ahead of print]

391.	Hepatitis C Competency and Outreach of Occupational Health Nurses
	Surjadi M¹, Nuchols B², Souza D, Wolfe L³, Burgel B¹. Workplace Health Saf. 2019 Jun 10:2165079919841637. doi: 10.1177/2165079919841637. [Epub ahead of print]

392.	Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors
	Frager SZ¹, Dhand A², Gass A³, Levine A³, Spielvogel D⁴, Nog R², Wolf DC⁵, Bodin RI⁵. Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255.

393.	Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
	McGlynn EA¹, Adams JL², Kramer J², Sahota AK³, Silverberg MJ⁴, Shenkman E⁵, Nelson DR⁶. JAMA Netw Open. 2019 Jun 5;2(6):e194765. doi: 10.1001/jamanetworkopen.2019.4765.

394.	A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY)
	Wilson E¹, Covert E², Hoffmann J¹, Comstock E¹, Emmanuel B¹, Tang L¹, Husson J¹, Chua J¹, Price A¹, Mathur P¹, Rosenthal E¹, Kattakuzhy S¹, Masur H³, Kottilil S¹. J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307-1. doi: 10.1016/j.jhep.2019.05.021. [Epub ahead of print]

395.	Willingness to participate in hepatitis C vaccine trials among socially marginalized people who use drugs
	Yakovenko I¹, Hyshka E¹, Tyrrell L², Wild TC³. J Subst Abuse Treat. 2019 Jun;101:67-71. doi: 10.1016/j.jsat.2019.03.010. Epub 2019 Mar 27.

396.	Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs
	Jost JJ¹, Tempalski B², Vera T³, Akiyama MJ⁴, Mangalonzo AP⁵, Litwin AH^6,7. Int J Environ Res Public Health. 2019 Jun 2;16(11). pii: E1958. doi: 10.3390/ijerph16111958.

397.

Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study

Persico M¹, Aglitti A¹, Milella M², Coppola C³, Messina V⁴, Claar E⁵, Gentile I⁶, Sogari F⁷, Pierri P⁸, Surace LA⁹, Morisco F¹⁰, Tundo P¹¹, Brancaccio G¹², Serviddio G¹³, Gatti P¹⁴, Termite AP¹⁵, Di Costanzo GG¹⁶, Caroleo B¹⁷, Cozzolongo R¹⁸, Coppola N¹⁹, Longo A²⁰, Fontanella L²¹, Federico A²², Rosato V^1,5, Terrenato I²³, Masarone M¹. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14170. [Epub ahead of print]

398.	The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance
	Stopka TJ¹, Jacque E², Kelso P³, Guhn-Knight H⁴, Nolte K⁵, Hoskinson R Jr⁴, Jones A³, Harding J⁶, Drew A⁷, VanDonsel A³, Friedmann PD⁴. Prev Med. 2019 May 31:105740. doi: 10.1016/j.ypmed.2019.05.028. [Epub ahead of print]

399.	Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs
	Coffin PO^1,2, Santos GM^1,2, Behar E¹, Hern J¹, Walker J¹, Matheson T¹, Kinnard EN^1,3, Silvis J¹, Vittinghoff E², Fox R², Page K². PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.

400.	Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic
	Lazenby GB¹, Orr C¹, Guille C¹, Meissner EG¹. South Med J. 2019 Jun;112(6):325-330. doi: 10.14423/SMJ.0000000000000988.

401.	Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States - a Rural and Urban Comparison
	Fraser H¹, Vellozzi C², Hoerger TJ³, Evans JL⁴, Kral AH³, Havens J⁵, Young AM^5,6, Stone J¹, Handanagic S⁷, Hariri S⁸, Barbosa C³, Hickman M¹, Leib A⁹, Martin NK^1,10, Nerlander L⁷, Raymond HF¹¹, Page K¹², Zibbell J³, Ward JW^8,13, Vickerman P¹. Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]

402.	Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study
	Williams B¹, Howell J², Doyle J³, Thompson AJ⁴, Draper B⁵, Layton C⁶, Latham N⁷, Bramwell F⁶, Membrey D⁶, Mcpherson M⁸, Roney J⁹, Stoové M⁵, Hellard ME¹⁰, Pedrana A¹¹. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30134-3. doi: 10.1016/j.drugpo.2019.05.012. [Epub ahead of print]

403.

Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs

Latham NH^1,2, Doyle JS^1,3, Palmer AY¹, Vanhommerig JW¹, Agius P^1,4, Goutzamanis S^1,4, Li Z¹, Pedrana A^1,5, Gottfredsson M^6,7,8, Bouscaillou J⁹, Luhmann N⁹, Mazhnaya A^10,11, Altice FL^12,13, Saeed S¹⁴, Klein M¹⁵, Falade-Nwulia OO¹⁶, Aspinall E^17,18, Hutchinson S^17,18, Hellard ME^1,3,5,19, Sacks-Davis R^1,4,20. Liver Int. 2019 May 24. doi: 10.1111/liv.14152. [Epub ahead of print]

404.	Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles
	Fuster D¹, Gelberg L^2,3. J Community Health. 2019 May 24. doi: 10.1007/s10900-019-00679-w. [Epub ahead of print]

405.	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project
	Rojas Rojas T¹, Di Beo V¹, Delorme J², Barre T¹, Mathurin P³, Protopopescu C¹, Bailly F⁴, Coste M¹, Authier N², Carrieri MP⁵, Rolland B⁶, Marcellin F¹. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30135-5. doi: 10.1016/j.drugpo.2019.05.013. [Epub ahead of print]

406.	The Swiss Hepatitis Strategy as a model for facing future health policy challenges
	Blindenbacher R¹, Maeschli B², Bruggmann P³. Health Policy. 2019 May 16. pii: S0168-8510(18)30417-2. doi: 10.1016/j.healthpol.2019.05.010. [Epub ahead of print]

407.	Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs
	Gutkind S¹, Schackman BR¹, Morgan JR², Leff JA¹, Agyemang L³, Murphy SM¹, Akiyama MJ³, Norton BL³, Litwin AH^4,5, Linas BP^2,6. Clin Infect Dis. 2019 May 16. pii: ciz384. doi: 10.1093/cid/ciz384. [Epub ahead of print]

408.	Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons
	Assoumou SA^1,2, Tasillo A¹, Vellozzi C³, Yazdi GE¹, Wang J¹, Nolen S¹, Hagan L⁴, Thompson W⁴, Randall LM⁵, Strick L^6,7, Salomon JA⁸, Linas BP^1,2,9.

409.	Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE
	Teixeira PA¹, Bresnahan MP², Laraque F², Litwin AH³, Shukla SJ³, Schwartz JM³, Reynoso S³, Perumalswami PV⁴, Weiss JM⁴, Wyatt B⁴, Schackman BR¹. Learn Health Syst. 2018 Jul;2(3). pii: e10056. doi: 10.1002/lrh2.10056. Epub 2018 May 10.

410.	Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
	Luo A¹, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Medicine (Baltimore). 2019 May;98(20):e15626. doi: 10.1097/MD.0000000000015626.

411.	Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona
	Tsang CA¹, Khan MA, Brady SM, Erhart LM, Komatsu KK. J Public Health Manag Pract. 2019 May 14. doi: 10.1097/PHH.0000000000001011. [Epub ahead of print]

412.	Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response
	Williams J¹, Lucarelli N², Nicoll A^1,2, Lubel J^1,2. Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.

413.	Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)
	Costa M^1,2, Rojas Rojas T^1,2, Lacoste D³, Villes V^1,2, Aumaitre H⁴, Protopopescu C^1,2, Yaya I^1,2, Wittkop L^5,6, Krause J⁷, Salmon-Céron D^8,9, Marcellin F^1,2, Sogni P^8,10,11, Carrieri MP^1,2; ANRS CO13 HEPAVIH Study Group. Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]

414.	The Global State of Harm Reduction in Prisons
	Sander G¹, Shirley-Beavan S¹, Stone K¹. J Correct Health Care. 2019 Apr;25(2):105-120. doi: 10.1177/1078345819837909.

415.	Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates
	Moore MS¹, Greene SK², Bocour A³, Brown CM⁴, Coyle JR⁵, Kuncio D⁶, Onofrey S⁷, Patel MT⁸, Winters A⁹. J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124. [Epub ahead of print]

416.	Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors
	Sise ME¹, Strohbehn IA², Bethea E², Gustafson JL², Chung RT². Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.

417.	Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home
	Ryan KL¹, Jakeman B², Conklin J³, Pineda LJ⁴, Deming P⁵, Mercier RC⁵. Am J Health Syst Pharm. 2019 May 4. pii: zxz059. doi: 10.1093/ajhp/zxz059. [Epub ahead of print]

418.	Hepatitis C Update and Expanding the Role of Primary Care
	Simoncini GM¹, Koren DE². J Am Board Fam Med. 2019 May-Jun;32(3):428-430. doi: 10.3122/jabfm.2019.03.180286.

419.	Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017
	Bartholomew TS^1,2, Grosgebauer K², Huynh K³, Cos T^3,4. Infect Dis (Auckl). 2019 Apr 28;12:1178633719841381. doi: 10.1177/1178633719841381. eCollection 2019.

420.	Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
	Pearlman B¹, Perrys M², Hinds A³. Am J Gastroenterol. 2019 May 8. doi: 10.14309/ajg.0000000000000248. [Epub ahead of print]

421.	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States
	Mukhtar NA¹, Ness EM¹, Jhaveri M¹, Fix OK¹, Hart M¹, Dale C¹, Pratt C², Kowdley KV³. Ann Hepatol. 2019 Mar - Apr;18(2):360-365. doi: 10.1016/j.aohep.2018.12.003. Epub 2019 Apr 17.

422.	Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
	Hahn JA¹, Tully DC², Evans JL³, Morris MD³, Briceno A³, Bean DJ⁴, Allen TM⁴, Page K⁵. Open Forum Infect Dis. 2019 Apr 25;6(4):ofz125. doi: 10.1093/ofid/ofz125. eCollection 2019 Apr.

423.	The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
	Gidwani-Marszowski R^1,2,3, Owens DK^4,5, Lo J⁶, Goldhaber-Fiebert JD⁵, Asch SM^4,7, Barnett PG^6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]

424.	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures
	Pawlotsky JM^1,2. Semin Liver Dis. 2019 Apr 30. doi: 10.1055/s-0039-1687823. [Epub ahead of print]

425.	High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial
	Varajic B¹, Cavallazzi R², Mann J², Furmanek S³, Guardiola J², Saad M². J Crit Care. 2019 Apr 15;52:186-192. doi: 10.1016/j.jcrc.2019.04.006. [Epub ahead of print]

426.	Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment
	Voils CI^1,2, King HA^3,4,5, Thorpe CT^6,7, Blalock DV^3,8, Kronish IM⁹, Reeve BB⁴, Boatright C³, Gellad ZF^3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]

427.	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study
	Trickey A¹, Fraser H², Lim AG², Peacock A³, Colledge S³, Walker JG², Leung J⁴, Grebely J⁵, Larney S³, Martin NK⁶, Hickman M⁷, Degenhardt L³, May MT⁸, Vickerman P⁷. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]

428.	Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
	E Williams B¹, Nelons D², Seaman A³, Witkowska M⁴, Ronan W⁵, Wheelock H⁵, Zaman A³, Garcia J². Int J Drug Policy. 2019 Apr 15. pii: S0955-3959(19)30074-X. doi: 10.1016/j.drugpo.2019.03.015. [Epub ahead of print]

429.	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study
	Bajis S¹, Grebely J¹, Cooper L², Smith J², Owen G², Chudleigh A², Hajarizadeh B¹, Martinello M¹, Adey S³, Read P⁴, Gilliver R⁴, Applegate T¹, Treloar C⁵, Maher L¹, Dore GJ¹. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]

430.	Quantitative evaluation of an integrated nurse model of care providing hepatitis Ctreatment to people attending homeless services in Melbourne, Australia
	Harney BL¹, Whitton B², Lim C³, Paige E², McDonald B⁴, Nolan S⁵, Pemberton D⁵, Hellard ME⁶, Doyle JS⁶. Int J Drug Policy. 2019 Apr 10. pii: S0955-3959(19)30077-5. doi: 10.1016/j.drugpo.2019.02.012. [Epub ahead of print]

431.	Liver Fibrosis Determination
	Lai M¹, Afdhal NH². Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.

432.	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis
	Weinberg EM¹, Palecki J¹, Reddy KR¹. Semin Liver Dis. 2019 May;39(2):195-208. doi: 10.1055/s-0039-1679934. Epub 2019 Apr 12.

433.	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis
	Back D¹, Belperio P², Bondin M³, Negro F⁴, Talal AH⁵, Park C³, Zhang Z³, Pinsky B³, Crown E³, Mensa FJ³, Marra F¹. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]

434.	Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
	Younis IR^1,2, Lakota EA^1,3, Volpe DA¹, Patel V¹, Xu Y¹, Sahajwalla CG¹. J Clin Pharmacol. 2019 Apr 11. doi: 10.1002/jcph.1405. [Epub ahead of print]

435.	Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES
	Butt AA^1,2,3, Yan P¹, Aslam S¹, Shaikh OS¹, Abou-Samra AB^2,3. Clin Infect Dis. 2019 Apr 12. pii: ciz304. doi: 10.1093/cid/ciz304. [Epub ahead of print]

436.	Hepatitis C in pregnant American Indian and Alaska native women; 2003-2015
	Nolen LD¹, O'Malley JC², Seeman SS¹, Bruden DJT¹, Apostolou A^3,4, McMahon BJ⁵, Bruce MG¹. Int J Circumpolar Health. 2019 Dec;78(1):1608139. doi: 10.1080/22423982.2019.1608139.

437.	HIV and HCV screening among trauma patients
	Simoncini GM¹, Oyola-Jimenez J¹, Singleton D¹, Volgraf J², Ramsey FV³, Goldberg A⁴. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]

438.	Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2
	Rogal SS^1,2,3, Yakovchenko V⁴, Waltz TJ^5,6, Powell BJ⁷, Gonzalez R⁸, Park A⁹, Chartier M¹⁰, Ross D¹⁰, Morgan TR⁸, Kirchner JE¹¹, Proctor EK¹², Chinman MJ^13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.

439.	Health implications of sex trading characteristics in Long Beach, California, USA
	Clingan SE¹, Fisher DG^2,3, Hardan-Khalil K⁴, Reynolds GL^3,5, Huckabay L⁴, Costa C⁴, Pedersen WC², Johnson ME⁶. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]

440.	Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting
	Overton K¹, Clegg J², Pekin F², Wood J², McGrath C², Lloyd A³, Post JJ⁴. Int J Drug Policy. 2019 Apr 6. pii: S0955-3959(19)30078-7. doi: 10.1016/j.drugpo.2019.02.013. [Epub ahead of print]

441.	Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston
	Beiser ME¹, Smith K², Ingemi M³, Mulligan E⁴, Baggett TP⁵. Int J Drug Policy. 2019 Apr 5. pii: S0955-3959(19)30079-9. doi: 10.1016/j.drugpo.2019.03.017. [Epub ahead of print]

442.	Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey
	Kasting ML¹, Giuliano AR², Reich RR³, Roetzheim RG⁴, Duong LM⁵, Thomas E⁶, Nelson DR⁷, Shenkman E⁸, Vadaparampil ST⁹. Cancer Epidemiol. 2019 Apr 3;60:112-120. doi: 10.1016/j.canep.2019.03.007. [Epub ahead of print]

443.	Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois
	McLuckie C^1,2, Pho MT^3,4, Ellis K⁵, Navon L^6,7, Walblay K⁸, Jenkins WD⁹, Rodriguez C¹⁰, Kolak MA¹¹, Chen YT¹², Schneider JA¹³, Zahnd WE^14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.

444.	Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study
	Simmons R^1,2, Ireland G^1,2, Ijaz S^3,2, Ramsay M¹, Mandal S^1,2; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections. J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096. [Epub ahead of print]

445.	Quality of Life, Functioning, and Coping in HCV Patients Continuing Versus Ceasing Alcohol Use
	Sims OT^1,2, Oh H³, Pollio DE¹, Hong BA⁴, Pollio EW¹, North CS^5,6. Health Promot Pract. 2019 Mar 21:1524839919837968. doi: 10.1177/1524839919837968. [Epub ahead of print]

446.	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
	Casey JL¹, Feld JJ^2,3, MacParland SA^4,5. Cells. 2019 Apr 5;8(4). pii: E317. doi: 10.3390/cells8040317.

447.	Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated
	Morris MD¹, Mirzazadeh A², Evans JL³, Briceno A³, Coffin P⁴, Hahn JA⁵, Page KA⁶. Drug Alcohol Depend. 2019 Feb 27;198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. [Epub ahead of print]

448.

Abara WE¹, Trujillo L², Broz D², Finlayson T², Teshale E¹, Paz-Bailey G², Glick S³, Al-Tayyib AA⁴, Robinson WT⁵, Masiello-Schuette S⁶, Sey EK⁷, Anderson BJ⁸, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]

J⁹, Braunstein S¹⁰.

449.	Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans
	Bendich I¹, Takemoto S², Patterson JT¹, Monto A³, Barber TC¹, Kuo AC². J Arthroplasty. 2019 Mar 9. pii: S0883-5403(19)30208-6. doi: 10.1016/j.arth.2019.02.052. [Epub ahead of print]

450.	Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
	Eckardt P¹, Niu J², Savage A¹, Griffin T¹, Sherman E^1,3. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219835590. doi: 10.1177/2325958219835590.

451.

Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia

Doyle JS^1,2, Scott N^2,3, Sacks-Davis R², Pedrana AE^2,3, Thompson AJ^4,5, Hellard ME^1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]

Collaborators (10)

452.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Thabut D¹, Bureau C², Layese R³, Bourcier V⁴, Hammouche M⁴, Cagnot C⁵, Marcellin P⁶, Guyader D⁶, Pol S⁷, Larrey D⁸, De Lédinghen V⁹, Ouzan D¹⁰, Zoulim F¹¹, Roulot D¹², Tran A¹³, Bronowicki JP¹⁴, Zarski JP¹⁵, Goria O¹⁶, Calès P¹⁷, Péron JM¹⁸, Alric L¹⁹, Bourlière M²⁰, Mathurin P²¹, Blanc JF²², Abergel A²³, Serfaty L²⁴, Mallat A³, Grangé JD²⁵, Attali P²⁶, Bacq Y²⁷, Wartelle-Bladou C²⁸, Dao T²⁹, Pilette C³⁰, Silvain C³¹, Christidis C³², Capron D³³, Bernard-Chabert B³⁴, Hillaire S³⁵, Di Martino V³⁶, Sutton A³⁷, Audureau E³, Roudot-Thoraval F³, Nahon P⁴; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]

453.	Comparative effectiveness of pharmacist care delivery models for hepatitis Cclinics
	Naidjate SS¹, Zullo AR², Dapaah-Afriyie R¹, Hersey ML¹, Marshall BDL³, Winkler RM¹, Berard-Collins C⁴. Am J Health Syst Pharm. 2019 Mar 15. pii: zxz034. doi: 10.1093/ajhp/zxz034. [Epub ahead of print]

454.	Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
	Younossi ZM¹, Henry L¹, P Ong J², Tanaka A³, Eguchi Y⁴, Mizokami M³, Lim YS⁵, Dan YY⁶, Yu ML⁷, Stepanova M⁸. Aliment Pharmacol Ther. 2019 Mar;49(6):644-653. doi: 10.1111/apt.15131. Epub 2019 Feb 13.

455.	The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment
	Woodward EN^1,2, Matthieu MM^3,4, Uchendu US⁵, Rogal S^6,7,8, Kirchner JE^3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.

456.	Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
	Jones EA¹, Linas BP², Truong V³, Burgess JF¹, Lasser KE^2,3. PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.

457.	Increasing access for veterans with hepatitis C by enhancing use of clinical pharmacy specialists
	Ourth HL, Groppi JA, Morreale AP, Jorgenson T, Himsel AS, Jacob DA. J Am Pharm Assoc (2003). 2019 Mar 7. pii: S1544-3191(19)30028-7. doi: 10.1016/j.japh.2019.01.018. [Epub ahead of print]

458.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]

459.	Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population
	Mokkarala S^1,2, Johnson C³, Sarkar S³, Rudas RJ⁴. J Correct Health Care. 2019 Mar 13:1078345819832875. doi: 10.1177/1078345819832875. [Epub ahead of print]

460.	Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017
	Bixler D¹, Annambholta P², Abara WE¹, Collier MG¹, Jones J², Mixson-Hayden T¹, Basavaraju SV², Ramachandran S¹, Kamili S¹, Moorman A¹. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]

461.	Fibrosis reversal after hepatitis C virus elimination
	Rockey DC¹. Curr Opin Gastroenterol. 2019 Mar 6. doi: 10.1097/MOG.0000000000000524. [Epub ahead of print]

462.	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
	Park A¹, Gonzalez R¹, Chartier M¹, Rogal S¹, Yakovchenko V¹, Ross D¹, Morgan TR¹. Fed Pract. 2018 Jul;35(7):24-29.

463.	Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review
	Francis-Graham S^1,2,3, Ekeke NA⁴, Nelson CA⁵, Lee TY⁵, Haj SE⁴, Rhodes T⁶, Vindrola C⁷, Colbourn T⁸, Rosenberg W^9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.

464.	Short-term budget affordability of hepatitis C treatments for state Medicaid programs
	Chou JW¹, Silverstein AR², Goldman DP². BMC Health Serv Res. 2019 Feb 28;19(1):140. doi: 10.1186/s12913-019-3956-x.

465.	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers
	Sandmann L^1,2, Dörge P^1,2, Wranke A^1,2, Vermehren J^3,2, Welzel TM^3,2, Berg CP^4,2, Grottenthaler JM^4,2, Weiss KH^5,2, Langel J^5,2, Sterneck M^6,2, von Wulffen M^6,2, Manns MP^1,2, Wedemeyer H^1,7,2, Hardtke S^1,2, von Hahn T^1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]

466.	Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
	Dellay B¹, Sexter A², Wang JH³, Hess GP^4,5, Kim WR⁶, Israni AK^3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]

467.

Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study

Ide T¹, Koga H², Nakano M¹, Hashimoto S³, Yatsuhashi H³, Higuchi N⁴, Nakamuta M⁴, Oeda S⁵, Eguchi Y⁵, Shakado S⁶, Sakisaka S⁶, Yoshimaru Y⁷, Sasaki Y⁷, Honma Y⁸, Harada M⁸, Seike M⁹, Maeshiro T¹⁰, Miuma S¹¹, Nakao K¹¹, Mawatari S¹², Ido A¹², Nagata K¹³, Matsumoto S¹⁴, Takami Y¹⁵, Sohda T¹⁶, Kakuma T¹⁷, Torimura T¹. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]

468.	Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
	Wei L¹, Kumada H², Perumalswami PV³, Tanwandee T⁴, Cheng W⁵, Heo J⁶, Cheng PN⁷, Hwang P⁸, Mu SM⁹, Zhao XM⁹, Asante-Appiah E⁸, Caro L⁸, Hanna GJ⁸, Robertson MN⁸, Haber BA⁸, Talwani R⁸. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]

469.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
	Lawitz E¹, Gane E², Cohen E³, Vierling J⁴, Agarwal K⁵, Hassanein T⁶, Mantry PS⁷, Pockros PJ⁸, Bennett M⁹, Kemmer N¹⁰, Morelli G¹¹, Zha J³, Wang D³, Shulman NS³, Cohen DE³, Reddy KR¹². Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.

470.	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation
	Latt NL¹. Gastroenterol Hepatol (N Y). 2018 Dec;14(12):687-705.

471.

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

Bernstein DE¹, Tran A², Martin P³, Kowdley KV⁴, Bourliere M⁵, Sulkowski MS⁶, Pockros PJ⁷, Renjifo B⁸, Wang D⁸, Shuster DL⁸, Cohen DE⁸, Jacobson IM⁹. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

472.	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
	Park A¹, Gonzalez R¹, Chartier M¹, Rogal S¹, Yakovchenko V¹, Ross D¹, Morgan TR¹. Fed Pract. 2018 Jul;35(7):24-29.

473.	Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
	Dellay B¹, Sexter A², Wang JH³, Hess GP^4,5, Kim WR⁶, Israni AK^3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]

474.	Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
	Wei L¹, Kumada H², Perumalswami PV³, Tanwandee T⁴, Cheng W⁵, Heo J⁶, Cheng PN⁷, Hwang P⁸, Mu SM⁹, Zhao XM⁹, Asante-Appiah E⁸, Caro L⁸, Hanna GJ⁸, Robertson MN⁸, Haber BA⁸, Talwani R⁸. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]

475.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
	Lawitz E¹, Gane E², Cohen E³, Vierling J⁴, Agarwal K⁵, Hassanein T⁶, Mantry PS⁷, Pockros PJ⁸, Bennett M⁹, Kemmer N¹⁰, Morelli G¹¹, Zha J³, Wang D³, Shulman NS³, Cohen DE³, Reddy KR¹². Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.

476.	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
	Bernstein DE¹, Tran A², Martin P³, Kowdley KV⁴, Bourliere M⁵, Sulkowski MS⁶, Pockros PJ⁷, Renjifo B⁸, Wang D⁸, Shuster DL⁸, Cohen DE⁸, Jacobson IM⁹. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

477.	Vitamin D deficiency and health-related quality of life in chronic hepatitis C
	Palazzo D¹, Biliotti E¹, Esvan R¹, Volpicelli L¹, Franchi C¹, Fontanelli Sulekova L¹, Spaziante M¹, Santori M¹, Rugova A¹, Rucci P², Taliani G¹. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]

478.	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
	Day E¹, Broder T², Bruneau J³, Cruse S¹, Dickie M⁴, Fish S⁴, Grillon C⁵, Luhmann N⁵, Mason K⁶, McLean E⁷, Trooskin S⁸, Treloar C⁹, Grebely J¹⁰. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]

479.	Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
	Childs E¹, Assoumou SA², Biello KB^3,4,5, Biancarelli DL^1,6, Drainoni ML^1,2,6,7, Edeza A^3,4, Salhaney P³, Mimiaga MJ^3,4,5,8, Bazzi AR⁹. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.

480.	Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
	Kumthekar A¹, Shull S², Lovejoy TI^2,3, Morasco BJ^2,3, Chang M^2,3, Barton J^2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]

481.	Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
	Ferenci P¹, Bourgeois S², Buggisch P³, Norris S⁴, Curescu M⁵, Larrey D⁶, Marra F⁷, Kleine H⁸, Dorr P⁹, Charafeddine M⁹, Crown E⁹, Bondin M⁹, Back D⁷, Flisiak R¹⁰. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]

482.	Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival
	Robbins JR^1,2, Schmid RK², Hammad AY³, Gamblin TC³, Erickson BA². Cancer Med. 2019 Jan 31. doi: 10.1002/cam4.1948. [Epub ahead of print]

483.	Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project
	Kempf MC¹, Ott C², Wise JM², Footman AP³, Araya BY³, Hardy CM⁴, Walker C⁴, Latham C⁵, Stockett R⁵, Daniels G⁵, Alexander M⁵, Lanzi RG³. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.

484.	Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
	Lawitz E¹, Poordad F¹, Anderson LJ², Vesay M², Kelly MM², Liu H², Gao W², Fernsler D², Asante-Appiah E², Robertson MN², Hanna GJ², Barr E², Butterton J², Kowdley KV³, Hassanein T⁴, Sahota A⁵, Gordon SC⁶, Yeh WW². J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]

485.	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
	Grebely J¹, Dore GJ², Alami NN³, Conway B⁴, Dillon JF⁵, Gschwantler M⁶, Felizarta F⁷, Hézode C⁸, Tomasiewicz K⁹, Fredrick LM³, Dumas EO³, Mensa FJ³. Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]

486.	Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection
	Nguyen J¹, Barritt Iv AS², Jhaveri R³. J Pediatr. 2019 Feb 6. pii: S0022-3476(18)31729-3. doi: 10.1016/j.jpeds.2018.12.012. [Epub ahead of print]

487.	Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States
	Chaillon A¹, Rand EB², Reau N³, Martin NK¹,⁴. Clin Infect Dis. 2019 Jan 28. doi: 10.1093/cid/ciz063. [Epub ahead of print]

488.	A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
	Powell D¹, Alpert A², Pacula RL³. Health Aff (Millwood). 2019 Feb;38(2):287-294. doi: 10.1377/hlthaff.2018.05232.

489.	Hepatitis C Virus: No Longer a Barrier to Oncology Care
	Laique SN¹, Vargas HE¹. Am J Gastroenterol. 2019 Feb;114(2):207-208. doi: 10.14309/ajg.0000000000000095.

490.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1

Shah ND¹, Ventura-Cots M², Abraldes JG³, Alboraie M⁴, Alfadhli A⁵, Argemi J⁶, Badia-Aranda E⁷, Soler EA⁸, Barritt AS 4th¹, Bessone F⁹, Biryukova M¹⁰, Carrilho FJ¹¹, Fernández MC⁸, Guiridi ZD¹⁰, El Kassas M¹², Eng-Kiong T¹³, Farias A¹¹, George J¹⁴, Gui W¹⁵, Thurairajah PH¹³, Hsiang JC¹³, Husic-Selimovic A¹⁶, Isakov V¹⁰, Karoney M¹⁷, Kim W¹⁸, Kluwe J¹⁹, Kochhar R²⁰, Dhaka N²⁰, Costa PM²¹, Nabeshima MA¹¹, Ono SK¹¹, Reis D²¹, Rodil A¹¹, Domech CR⁸, Sáez-Royuela F⁷, Scheurich C¹⁹, Siow W¹⁴, Sivac-Burina N¹⁶, Dos Santos Traquino ES⁸, Some F¹⁷, Spreckic S¹⁶, Tan S²², Vorobioff J⁹, Wandera A¹⁷, Wu P²², Yakoub M¹², Yang L¹⁵, Yu Y²², Zahiragic N¹⁶, Zhang C²², Cortez-Pinto H²¹, Bataller R²³. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30073-4. doi: 10.1016/j.cgh.2019.01.026. [Epub ahead of print]

491.	Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
	Shaheen AA¹, Nguyen HH¹, Congly SE¹, Kaplan GG¹, Swain MG¹. Liver Int. 2019 Jan 28. doi: 10.1111/liv.14054. [Epub ahead of print]

492.	Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals
	Ottman AA¹, Townsend ML¹, Hashem MG¹, Britt RB¹. Ann Pharmacother. 2019 Jan 17:1060028018824988. doi: 10.1177/1060028018824988. [Epub ahead of print]

493.	The successful scale-up of direct-acting antiviral hepatitis C treatments will benefit from concerted investments in implementation science
	Knight R¹, Ti M². Can J Public Health. 2019 Jan 8. doi: 10.17269/s41997-018-0164-0. [Epub ahead of print]

494.	Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care
	Tasillo A¹, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, Randall L, Salomon JA, Linas BP. Obstet Gynecol. 2019 Feb;133(2):289-300. doi: 10.1097/AOG.0000000000003062.

495.	Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care
	Kushner T¹, Terrault NA². Hepatol Commun. 2018 Nov 30;3(1):20-28. doi: 10.1002/hep4.1282. eCollection 2019 Jan.

496.	The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA
	Coyle C¹,², Moorman AC³, Bartholomew T², Klein G⁴, Kwakwa H⁵, Mehta SH¹, Holtzman D³. Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501. [Epub ahead of print]

497.	Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
	Rosenberg ES¹, Rosenthal EM¹, Hall EW², Barker L³, Hofmeister MG³, Sullivan PS², Dietz P⁴, Mermin J⁴, Ryerson AB³. JAMA Netw Open. 2018 Dec 7;1(8):e186371. doi: 10.1001/jamanetworkopen.2018.6371.

498.	Treating HCV Infection: It Doesn't Get Much Better Than This
	Naggie S¹. Top Antivir Med. 2019 Jan;26(4):104-108.

499.	Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program
	Burton MJ¹, Voluse AC², Anthony V³. J Subst Abuse Treat. 2019 Mar;98:9-14. doi: 10.1016/j.jsat.2018.11.008. Epub 2018 Nov 20.

500.	Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients
	Shoreibah M¹, Romano J², Sims OT³,⁴,⁵, Guo Y⁶, Jones D⁷, Venkata K², Kommineni V², Orr J⁸, Fitzmorris P¹, Massoud OI¹. J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11.

501.	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
	Mathur P¹, Kottilil S¹, Wilson E¹. J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437. doi: 10.14218/JCTH.2018.00007. Epub 2018 Sep 27.

502.	Machine learning models to predict disease progression among veterans with hepatitis C virus
	Konerman MA¹, Beste LA², Van T³, Liu B⁴, Zhang X⁴, Zhu J⁴, Saini SD¹,³, Su GL¹,³, Nallamothu BK⁵,⁶, Ioannou GN⁷,⁸, Waljee AK¹,³,⁶. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.

503.	HCV therapy: no one to let behind
	Bourlière M¹, Pietri O². Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print]

504.	Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review
	Murdock RM¹, Brizzi MB¹, Perez O¹, Badowski ME². Infect Dis Ther. 2019 Jan 3. doi: 10.1007/s40121-018-0228-8. [Epub ahead of print]

505.	High resolution evolutionary analysis of within-host hepatitis C virus infection
	Raghwani J¹, Wu CH², Ho CKY³, De Jong M³, Molenkamp R³, Schinkel J³, Pybus OG⁴, Lythgoe KA¹. J Infect Dis. 2019 Jan 2. doi: 10.1093/infdis/jiy747. [Epub ahead of print]

506.	Heavy Drinking and Treatment among HIV/HCV Co-Infected Patients
	Elliott JC¹,², Shalev N³, Hasin DS¹,²,⁴. J Subst Abus Alcohol. 2018;6(2). pii: 1079. Epub 2018 Jul 26.

507.	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus
	Li DK¹, Chung RT². Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.

508.	Hepatitis C and pregnancy outcomes: a systematic review protocol
	Parent S¹, Salters K¹,², Awendila L¹, Ti L³,⁴. BMJ Open. 2018 Dec 22;8(12):e024288. doi: 10.1136/bmjopen-2018-024288.

509.	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure
	Lim TR¹,², Hazlehurst JM³, Oprescu AI¹, Armstrong MJ¹,², Abdullah SF⁴, Davies NP⁵, Flintham R⁵, Balfe P¹, Mutimer DJ¹,², McKeating JA⁶, Tomlinson JW⁷. Clin Endocrinol (Oxf). 2018 Dec 26. doi: 10.1111/cen.13924. [Epub ahead of print]

510.	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
	Foster GR¹, Asselah T², Kopecky-Bromberg S³, Lei Y³, Asatryan A³, Trinh R³, Zadeikis N³, Mensa FJ³. PLoS One. 2019 Jan 2;14(1):e0208506. doi: 10.1371/journal.pone.0208506. eCollection 2019.

511.	Use of Hepatitis C AB-Positive Donor Liver in Hepatitis C Nonviremic Liver Transplant Recipients
	Luckett K¹, Kaiser T¹, Bari K¹, Safdar K¹, Schoech MR¹, Apewokin S¹, Diwan T¹, Cuffy MC¹, Anwar N¹, Shah SA². J Am Coll Surg. 2018 Dec 23. pii: S1072-7515(18)32228-2. doi: 10.1016/j.jamcollsurg.2018.12.004. [Epub ahead of print]

512.	Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C
	Li J¹, Gordon SC², Rupp LB³, Zhang T¹, Trudeau S¹, Holmberg SD⁴, Moorman AC⁴, Spradling PR⁴, Teshale EH⁴, Boscarino JA⁵, Schmidt MA⁶, Daida YG⁷, Lu M¹; CHeCS Investigators. Liver Int. 2018 Dec 20. doi: 10.1111/liv.14031. [Epub ahead of print]

513.	Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
	Cardona-Gonzalez MG¹, Goldman JD¹,², Narayan L¹, Brainard DM³, Kowdley KV¹. Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec.

514.	A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment
	Sullivan KM, Spooner LM, Harris E, Lowe K, Abraham GM. P T. 2018 Dec;43(12):764-768.

515.	Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
	Shetty A¹, Buch A², Saab S³,⁴,⁵. Dig Dis Sci. 2018 Dec 17. doi: 10.1007/s10620-018-5404-x. [Epub ahead of print]

516.	Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals
	Trivedi HD¹, Patwardhan VR², Malik R³. Dig Liver Dis. 2018 Nov 28. pii: S1590-8658(18)31235-0. doi: 10.1016/j.dld.2018.11.016. [Epub ahead of print]

517.	Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective
	Crowley D¹,²,³, Van Hout MC⁴,⁵, Lambert JS⁶,⁷, Kelly E⁸, Murphy C⁵,⁸, Cullen W⁶. Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.

518.	Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes
	Zuckerman A¹, Carver A¹, Chastain CA². Curr Treat Options Infect Dis. 2018;10(4):431-446. doi: 10.1007/s40506-018-0177-5. Epub 2018 Oct 18.

519.	Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago
	Couri T¹, Cotter TG², Chen D³, Hammes M⁴, Reddy B⁴, Josephson M⁴, Yeh H⁵, Chung RT⁶, Paul S². Am J Nephrol. 2018 Dec 14;49(1):32-40. doi: 10.1159/000495263. [Epub ahead of print]

520.	Management and treatment of the HCV-infected kidney transplant patient
	Wong T¹, Bloom RD¹. Semin Dial. 2018 Dec 9. doi: 10.1111/sdi.12766. [Epub ahead of print]

521.	Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy
	Cohen E¹, Liapakis A². Semin Dial. 2018 Dec 17. doi: 10.1111/sdi.12763. [Epub ahead of print]

522.	Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis Cvirus-infected donors into hepatitis C virus-negative patients
	Goldberg D¹,², Reese PP²,³. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12767. [Epub ahead of print]

523.

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

D'Ambrosio R¹, Pasulo L², Puoti M³, Vinci M⁴, Schiavini M⁵, Lazzaroni S², Soria A⁶, Gatti F⁷, Menzaghi B⁸, Aghemo A⁹, Capelli F¹⁰, Rumi MG¹¹, Morini L¹², Giorgini A¹³, Pigozzi MG¹⁴, Rossini A¹⁴, Maggiolo F², Pan A¹⁵, Memoli M¹⁶, Spinelli O¹⁷, Del Poggio P², Saladino V¹⁸, Spinetti A¹⁴, De Bona A¹³, Capretti A¹³, Uberti-Foppa C¹⁹, Bonfanti P²⁰, Terreni N²¹, Menozzi F²², Colombo AE¹⁷, Giglio O¹⁷, Centenaro R²³, Borghi M²⁴, Baiguera C³, Picciotto V⁴, Landonio S⁵, Gori A²⁵, Magnani C²⁶, Noventa F²⁷, Paolucci S²⁸, Lampertico P²⁴, Fagiuoli S²; NAVIGATORE-Lombardia Study Group. J Hepatol. 2018 Nov 23. pii: S0168-8278(18)32543-1. doi: 10.1016/j.jhep.2018.11.011. [Epub ahead of print]

524.	Hepatitis C: is eradication possible?
	Lombardi A¹,², Mondelli MU¹,²; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int. 2018 Nov 25. doi: 10.1111/liv.14011. [Epub ahead of print]

525.	Treating hepatitis C virus in dialysis patients: How, when, and why?
	Pagan J¹, Ladino M¹,², Roth D¹. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12764. [Epub ahead of print]

526.	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease
	Bruchfeld A¹, Lindahl K². Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12762. [Epub ahead of print]

527.	Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV
	Frost MC¹, Matson TE², Tsui JI³, Williams EC⁴. Drug Alcohol Depend. 2018 Oct 30;194:288-295. doi: 10.1016/j.drugalcdep.2018.10.008. [Epub ahead of print]

528.	The Revolution in Treatment of Hepatitis C
	Mayberry J¹, Lee WM². Med Clin North Am. 2019 Jan;103(1):43-55. doi: 10.1016/j.mcna.2018.08.007.

529.	Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016
	Assoumou SA¹, Wang J², Tasillo A², Eftekhari Yazdi G², Tsui JI³, Strick L⁴, Linas BP⁵. Am J Prev Med. 2018 Nov 12. pii: S0749-3797(18)32221-9. doi: 10.1016/j.amepre.2018.08.016. [Epub ahead of print]

530.	Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV
	Price JC¹, McKinney JE¹, Crouch PC², Dillon SM³, Radix A⁴, Stivala A⁴, Carollo JR⁵, Fierer DS⁵. J Infect Dis. 2018 Nov 20. doi: 10.1093/infdis/jiy670. [Epub ahead of print]

531.	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients
	Lybeck C¹, Brenndörfer ED², Sällberg M², Montgomery SM³,⁴,⁵, Aleman S⁶,⁷, Duberg AS¹. Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316. [Epub ahead of print]

532.	Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings
	Burrell CN¹, Sharon MJ¹, Davis SM¹, Wojcik EM¹, Martin IBK¹. West J Emerg Med. 2018 Nov;19(6):1057-1064. doi: 10.5811/westjem.2018.9.39512. Epub 2018 Oct 9.

533.

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

Stone J¹, Fraser H², Lim AG², Walker JG², Ward Z², MacGregor L², Trickey A², Abbott S², Strathdee SA³, Abramovitz D³, Maher L⁴, Iversen J⁴, Bruneau J⁵, Zang G⁶, Garfein RS³, Yen YF⁷, Azim T⁸, Mehta SH⁹, Milloy MJ¹⁰, Hellard ME¹¹, Sacks-Davis R¹², Dietze PM¹³, Aitken C¹³, Aladashvili M¹⁴, Tsertsvadze T¹⁵, Mrav?ík V¹⁶, Alary M¹⁷, Roy E¹⁸, Smyrnov P¹⁹, Sazonova Y¹⁹, Young AM²⁰, Havens JR²¹, Hope VD²², Desai M²³, Heinsbroek E²³, Hutchinson SJ²⁴, Palmateer NE²⁴, McAuley A²⁵, Platt L²⁶, Martin NK²⁷, Altice FL²⁸, Hickman M², Vickerman P². Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29.

534.	Identifying barriers to treatment of HCV in the primary care setting
	Johnson S¹,², Aluzaite K³, Taar A³, Schultz M³,⁴. Hepatol Int. 2018 Oct 30. doi: 10.1007/s12072-018-9902-x. [Epub ahead of print]

535.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
	Grebely J¹, Puoti M², Wedemeyer H³, Cooper C⁴, Sulkowski MS⁵, Foster GR⁶, Berg T⁷, Villa E⁸, Rodriguez-Perez F⁹, Wyles DL¹⁰, Schnell G¹¹, Alami NN¹¹, Zhang Z¹¹, Dumas E¹¹, Dore GJ¹. Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov.

536.	Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)
	Poordad F¹, Shiffman ML², Ghesquiere W³, Wong A⁴, Huhn GD⁵, Wong F⁶, Ramji A⁷, Shafran SD⁸, McPhee F⁹, Yang R⁹, Noviello S¹⁰, Linaberry M¹⁰; ALLY-3C study team. Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print]

537.	Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program
	Talal AH¹,², McLeod A², Andrews P², Nieves-McGrath H¹, Chen Y³, Reynolds A⁴, Sylvester C², Dickerson SS⁵, Markatou M³, Brown LS². Telemed J E Health. 2018 Oct 16. doi: 10.1089/tmj.2018.0161. [Epub ahead of print]

538.	Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges
	Baumert TF¹, Berg T², Lim JK³, Nelson DR⁴. Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35155-2. doi: 10.1053/j.gastro.2018.10.024. [Epub ahead of print]

539.	Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
	Tran TT¹, Mehta D²,³, Mensa F³, Park C³, Bao Y³, Sanchez Gonzalez Y⁴. Infect Dis Ther. 2018 Dec;7(4):473-484. doi: 10.1007/s40121-018-0218-x. Epub 2018 Oct 27.

540.	Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
	Palaniswami PM¹, El Sayed A¹, Asriel B¹, Carollo JR¹, Fierer DS¹; New York Acute Hepatitis C Surveillance Network.Collaborators (61) Open Forum Infect Dis. 2018 Sep 21;5(10):ofy238. doi: 10.1093/ofid/ofy238. eCollection 2018 Oct.

541.	Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?
	Ruggieri A¹, Gagliardi MC¹, Anticoli S¹. Front Immunol. 2018 Oct 8;9:2302. doi: 10.3389/fimmu.2018.02302. eCollection 2018

542.	Telementoring for hepatitis C treatment in correctional facilities
	Neuhaus M¹, Langbecker D¹, Caffery LJ¹, Taylor M¹, Garner L¹, Williams G², Smith AC¹, Macdonald GA³. J Telemed Telecare. 2018 Dec;24(10):690-696. doi: 10.1177/1357633X18795361.

543.	Care of Incarcerated Patients
	Davis DM¹, Bello JK¹, Rottnek F¹. Am Fam Physician. 2018 Nov 15;98(10):577-583.

544.	Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children
	Schillie SF¹, Canary L², Koneru A², Nelson NP², Tanico W³, Kaufman HW⁴, Hariri S², Vellozzi CJ². Am J Prev Med. 2018 Nov;55(5):633-641. doi: 10.1016/j.amepre.2018.05.029.

545.	The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease
	Younossi Z¹,², Papatheodoridis G³, Cacoub P⁴,⁵, Negro F⁶, Wedemeyer H⁷, Henry L⁸, Hatzakis A⁹,¹⁰. J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. doi: 10.1111/jvh.13005.

546.	Sex hormone levels by presence and severity of cirrhosis in women with chronic hepatitis Cvirus infection
	Sarkar M¹, Lai JC¹, Sawinski D², Zeigler TE³, Cedars M⁴, Forde KA⁵,⁶. J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027. [Epub ahead of print]

547.	Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States
	Young K¹, Liu B², Bhuket T², Gish RG³,⁴, Wong RJ². J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039. [Epub ahead of print]

548.	Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone
	Talal AH¹,², Andrews P², Mcleod A², Chen Y³, Sylvester C², Markatou M³, Brown LS². Clin Infect Dis. 2018 Oct 17. doi: 10.1093/cid/ciy899. [Epub ahead of print]

549.	National Trends in Liver Transplantation in Older Adults
	Haugen CE¹, Holscher CM¹, Garonzik-Wang J¹, Pozo M¹, Warsame F¹, McAdams-DeMarco M¹,², Segev DL¹,². J Am Geriatr Soc. 2018 Oct 16. doi: 10.1111/jgs.15583. [Epub ahead of print]

550.	Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis
	Flamm S¹, Mutimer D², Asatryan A³, Wang S³, Rockstroh J⁴, Horsmans Y⁵, Kwo PY⁶, Weiland O⁷, Villa E⁸, Heo J⁹, Gane E¹⁰, Ryder SD¹¹, Welzel TM¹², Ruane PJ¹³, Agarwal K¹⁴, Ng TI³, Xue Z³, Lovell SS³, Krishnan P³, Kopecky-Bromberg S³, Trinh R³, Mensa FJ³, Wyles DL¹⁵. J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038. [Epub ahead of print]

551.	The actual management of Hepatitis B and Hepatitis C in children
	Batsis ID¹, Wasuwanich P², Karnsakul WW³. Minerva Pediatr. 2018 Oct 18. doi: 10.23736/S0026-4946.18.05410-5. [Epub ahead of print]

552.	Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir
	Pearlman BL¹,²,³, Hinds AE¹. Aliment Pharmacol Ther. 2018 Nov;48(9):914-923. doi: 10.1111/apt.14977. Epub 2018 Oct 4.

553.	Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism
	Spaulding AC¹,², Chhatwal J³,⁴, Adee MG¹, Lawrence RT⁵, Beckwith CG⁶,⁷, Oehsen WV⁸. J Correct Health Care. 2018 Oct 15:1078345818805770. doi: 10.1177/1078345818805770. [Epub ahead of print]

554.	Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine
	Morey S¹,², Hamoodi A³, Jones D⁴, Young T¹, Thompson C⁴, Dhuny J⁵, Buchanan E¹, Miller C¹, Hewett M¹, Valappil M¹, Hunter E⁶, McPherson S¹,⁷. J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017. [Epub ahead of print]

555.	Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus
	Saab S¹,²,³,⁴, Ahn T¹,²,³,⁴, McDaniel T¹,²,³,⁴, Yanny B¹,²,³,⁴, Tong MJ¹,²,³,⁴. Gastroenterol Hepatol (N Y). 2018 Aug;14(8):459-462.

556.	Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S
	Park H¹, Wang W¹, Henry L¹, Nelson DR². Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303. [Epub ahead of print]

557.	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development
	Bailey JR¹, Barnes E², Cox AL¹. Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35035-2. doi: 10.1053/j.gastro.2018.08.060. [Epub ahead of print]

558.	Differences in Referral Access to Care Between Gastrointestinal Subspecialty Patients: Barriers and Opportunities
	Reddy K¹, Patrick C¹, Liaquat H¹, Rodriquez E¹, Stocker A¹, Cave B², Cave MC¹, Smart L¹, Cutts T³, Abell T¹. Health Equity. 2018 Jun 1;2(1):103-108. doi: 10.1089/heq.2018.0001. eCollection 2018.

559.	Elimination of Hepatitis C in Liver Transplant Recipients
	Saab S¹,², Challita Y¹, Chen PH², Jimenez MA², Lee AD², Saab EG², Ahn T², Choi G¹,², Durazo FA¹,², El-Kabany MM¹,², Han SB¹,², Grotts J¹, Agopian VG², Busuttil RW². J Clin Transl Hepatol. 2018 Sep 28;6(3):247-250. doi: 10.14218/JCTH.2017.00079. Epub 2018 Jun 8.

560.	Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
	Brown PR¹, Sadiq O¹, Weick A², Lenhart A¹, Elbatta M², Fernandez C², Kutait A², Pompa R², Jafri SM². Hepatol Commun. 2018 Sep 24;2(10):1172-1178. doi: 10.1002/hep4.1243. eCollection 2018 Oct.

561.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

Minutolo R¹, Aghemo A²,³, Chirianni A⁴, Fabrizi F⁵, Gesualdo L⁶, Giannini EG⁷, Maggi P⁸, Montinaro V⁶, Paoletti E⁹, Persico M¹⁰, Perticone F¹¹, Petta S¹², Puoti M¹³, Raimondo G¹⁴, Rendina M¹⁵, Zignego AL¹⁶; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print]

562.	Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative
	Wray D, Coppin JD, Scott D, Jacob DA, Jinadatha C. Jt Comm J Qual Patient Saf. 2018 Sep 25. pii: S1553-7250(18)30089-8. doi: 10.1016/j.jcjq.2018.06.005. [Epub ahead of print]

563.	Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use
	Des Jarlais DC¹, Arasteh K², Feelemyer J², McKnight C², Barnes DM², Perlman DC², Uuskula A³, Cooper HLF⁴, Tross S⁵. Drug Alcohol Depend. 2018 Sep 12;192:74-79. doi: 10.1016/j.drugalcdep.2018.07.034. [Epub ahead of print]

564.	Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
	Knight LL¹, Wagner K¹, Leyva Y¹, Bruce VR¹, White KAM¹, Talamantes YS¹, Price B¹, Page K¹, Carvour ML¹. Health Promot Pract. 2018 Nov;19(6):815-822. doi: 10.1177/1524839918799455. Epub 2018 Sep 18.

Triple E for HCV Treatment Expansion in High-Risk Communities